

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
22 July 2004 (22.07.2004)

PCT

(10) International Publication Number  
**WO 2004/061105 A1**

(51) International Patent Classification<sup>7</sup>: **C12N 15/12, 15/861, 5/16, C07K 14/71, C12P 21/02, A61K 38/17, 48/00**

Via Pontina Km. 30, 600, I-00040 Pomezia (Rome) (IT). LA MONICA, Nicola [IT/IT]; IRBM, Via Pontina Km. 30, 600, I-00040 Pomezia (Rome) (IT). MONACI, Paolo [IT/IT]; IRBM, Via Pontina Km. 30, 600, I-00040 Pomezia (Rome) (IT). NUZZO, Maurizio [IT/IT]; IRBM, Via Pontina Km. 30, 600, I-00040 Pomezia (Rome) (IT).

(21) International Application Number:  
**PCT/EP2003/014997**

(22) International Filing Date:  
**29 December 2003 (29.12.2003)**

(74) Agent: **MAN, Jocelyn; Merck & Co., Inc., European Patent Department, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB).**

(25) Filing Language:  
**English**

(26) Publication Language:  
**English**

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(30) Priority Data:  
**60/437,846 3 January 2003 (03.01.2003) US**

(71) Applicant (*for all designated States except US*): **ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA [IT/IT]**; Via Pontina Km. 30, 600, I-00040 Pomezia (Rome) (IT).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **CILIBERTO, Gennaro [IT/IT]; IRBM, Via Pontina Km. 30, 600, I-00040 Pomezia (Rome) (IT). LAHM, Armin [DE/IT]; IRBM,**

(84) Designated States (*regional*): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,

[Continued on next page]

(54) Title: RHESUS HER2/NEU, NUCLEOTIDES ENCODING SAME, AND USES THEREOF

Predicted Amino Acid Sequence of First Rhesus Her2/Neu Protein (SEQ ID NO:2)

1 MELAAWYRWG LLLALLPPGA AGTQVCTGTD MKLRLPASP E THLDMLRHLY QGCQVVQGNL  
61 ELTYLPTNAS LSFLQDQEV QGYVLIAHQV VRQVPLQLR IVRGTQLFED NYALAVLDNG  
121 DLLNNTPVT GASPGGLREL QLRSLTEILK GGVLIQRNPQ LCYQDTILWK DIFHKNNQLA  
181 LTLIDTNRSR ACHPCSPVCK GSRCWGESSE DCQSLTRTVC AGGCARCKGP LPTDCCHEQC  
241 AAGCTGPKHS DCLACLAHFHN SGICELHCPA LVTNTYNTDFE SMPNPEGRYT FGASCVTACP  
301 YNYLSTDVG5 CTLVCPLHNO EVTAEDGTQR CEKCSKPCAR VCYGLGMELH REVRAVTSAN  
361 IQEFAGCKKI FGSLAFLPES FDGDPAISNTA PLQPEQLRVE ETLEEITGYL YISAWPDSL  
421 DLSVLQLNQV IRGRILHNGA YSLTLQQLGI SWLGLRSLRE LGSGLALIHIIH NTRLCFVHTV  
481 PWDLFRNPH QALLHTANRP EDECVGEGGLA CHOLCARGHC WGPGPTQCVN CSQFLRGQEC  
541 VEECRVLQGL PREYVNRARHC LPCHEPECQPO NGSVTCFGPE ADQCVCACAHY KDPPFCVARC  
601 PSGVKPDLSY MPIWKFPDDEE GTCCSPINC THSCVLLDDK GCPAEQRASP LTSIIASAVG  
661 ILLVVVLGVV FGILIKRRQQ KIRKYTMRL LQTELVEPL TPSGAMPNQA QMRILKETEL  
721 RKVKVLGSGA FGTVYKGWI POGENVKIPV AIKVLRLENS PKANEILDE AYVMAGVGSP  
781 YVSRLLGICL TSTVQLVTQI MPYGCLLDHV RENRGRGLSQ DLLNWCMQIA KGMSSLEDVR  
841 LVHRDLAARN VLVKSPNHWK ITDFGLARLL DIDETEYHAD GGKVPIKWM LESILRRRT  
901 HQSDWWSYGV TWWEMLTFGA KPYDGIPARE IPDLLEKGER LPQPPPICTID VYMIMVKCWM  
961 IDSECRRPRFR ELVSEFSRMA RDQPRFVVIQ NEDLGPASPL DSTFYRSLL DDDMGDLVDA  
1021 EEYLVPQQGF FCPDPAPGTG GMVHRRRSS STRSGGGDLT LGLEPSEEAA PRSPRAPSEG  
1081 TGSDVFDGDL GMCAAKGLQS LPAHDPSLQ RYSEOPTVPL PSETDGYVAP LTCSPQPEYV  
1141 NOPDVRPQPP SPOEGPLSPA RPTGATLERP KTLSPGKNGV VKDVFAGGA VENPEYLAPR  
1201 GGAAPQPHLP PAFSPAFDNL YYWDQDPSER GAPPSTFKGT PTAENPEYLG LDVPV\*

(57) Abstract: Polynucleotides encoding rhesus monkey HER2/neu have been isolated, cloned and sequenced. The gene encoding the HER2/neu is commonly associated with the development of epithelial-derived human carcinomas. The present invention provides compositions and methods to elicit or enhance immunity to the protein product expressed by the HER2/neu tumor-associated antigen, wherein aberrant HER2/neu expression is associated with a carcinoma or its development. This invention specifically provides adenoviral vector constructs carrying rhHER2/neu and discloses their use in vaccines and pharmaceutical compositions for preventing and treating cancer.

WO 2004/061105 A1



ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

**Published:**

- with international search report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**TITLE OF THE INVENTION****RHESUS HER2/NEU, NUCLEOTIDES ENCODING SAME, AND USES THEREOF****CROSS-REFERENCE TO RELATED APPLICATIONS**

The present application claims priority to U.S. Serial No. 60/437,846, filed January 3, 2003, which is hereby incorporated by reference.

**FIELD OF THE INVENTION**

The present invention relates generally to the detection and therapy of cancer. More specifically, the present invention relates to the rhesus monkey homologue of the tumor associated polypeptide HER2/neu, to isolated nucleic acid molecules which encode this protein, and to recombinant vectors and hosts comprising DNA encoding this protein. This invention also relates to adenoviral vector constructs carrying rhesus HER2/neu and to their use in vaccines and pharmaceutical compositions for preventing and treating cancer.

**BACKGROUND OF THE INVENTION**

Cancer typically involves the deregulation of genes that contribute to maintaining the cell cycle or controlling cell proliferation, such as growth factors and their receptors, oncogenes and tumor suppressor genes. The products of many of these genes are expressed on the surface of a wide variety of tumor cells and, hence, were designated tumor-associated antigens (TAA). Recent evidence supports the existence of tumor-associated antigens that are capable of eliciting an immune response, making these molecules a target for vaccine therapy. Because many of these gene products are also expressed in normal cells, albeit at lower levels, many cancer vaccines targeting tumor-associated antigens have proven ineffective due to immunotolerance.

The product of the HER2/neu proto-oncogene (also called c-erbB-2) is a transmembrane TAA that is a member of the epidermal growth factor receptor family. The HER2/neu gene was originally cloned from a rat neuroblastoma (Shih et al., *Nature* 290: 261-264 (1981)) and later isolated and characterized from human cells (Coussens et al., *Science* 230: 1132-39 (1985); King et al., *Science* 229: 974-76 (1985)). To date, no simian homologs of HER2/neu are available.

HER2/neu has been further classified as a member of the HER family of receptor tyrosine kinases, which consists of four receptors that participate in cell growth and differentiation. The HER receptors contribute to maintaining normal cell growth by binding growth factor ligands as dimers, thereby initiating intracellular signaling cascades which

ultimately result in the activation of genes important in cell growth. Although several ligands have been identified for other members of the HER family, a high affinity ligand for the HER2/neu receptor has yet to be found (Lohrisch and Piccart, *Semin. Oncol.* 28(6): Suppl. 18: 3-11 (2001)).

Low levels of expression of the HER2/neu transcript and the encoded 185 kD protein were detected in normal adult epithelial cells of various tissues, including the skin and breast, and tissues of the gastrointestinal, reproductive and urinary tracts (Press et al., *Oncogene* 5: 953-962 (1990)). Higher levels of HER2/neu expression were also detected in the corresponding fetal tissues during embryonic development (Press et al., *supra*).

HER2/neu is commonly overexpressed or amplified in various malignancies such as carcinomas of the breast, ovary, uterus, colon, and prostate, and adenocarcinomas of the lung (reviewed in Disis and Cheever, *Adv. Cancer Research* 71: 343-371 (1997)). Such overexpression of HER2/neu correlates with a poor prognosis and a higher relapse rate for cancer patients (Slamon et al., *Science* 244: 707-712 (1989)).

Many cancer patients suffering from malignancies associated with HER2/neu overexpression have had immune responses against the protein product of the HER2/neu oncogene, thus making HER2/neu an immunological target for the development of cancer therapeutics. An effective vaccine exploiting this immune response to HER2/neu must both enhance this immunity to a level that is protective and/or preventive and overcome self-tolerance.

HER2/neu has been proposed as a target for the development of immunological treatments of different malignancies. Different anti-HER2 monoclonal antibodies have been investigated as therapies for breast cancer, with each antibody demonstrating various levels of success (for discussion, see Yarden, *Oncology* 61(suppl 2): 1-13 (2001)). Amici et al. (U.S. Patent No. 6,127,344) disclose a method for inducing immunity against HER2/neu by administering an expression vector comprising the full-length human HER2/neu cDNA functionally linked to the human cytomegalovirus promoter. Cheever and Disis disclose methods for immunizing humans against HER2/neu-associated cancers with HER2 peptides (U.S. Patent No. 5,846,538). Additionally, HER2/neu peptide-based vaccines have been studied in rodent models (for review, see Disis and Cheever, *Advances in Cancer Research* 71:343-71 (1997)).

Despite the identification of the HER2/neu clones mentioned above, it would be highly desirable to identify additional mammalian genes encoding HER2/neu to allow for the development of a cancer vaccine which is efficacious and not hindered by self-tolerance.

## SUMMARY OF THE INVENTION

The present invention relates to isolated or purified nucleic acid molecules (polynucleotides) comprising a sequence of nucleotides that encode a novel rhesus monkey HER2/neu protein (also called c-erbB-2, hereinafter designated rhHER2/neu) as set forth in SEQ ID NO:2 and SEQ ID NO:41. The DNA molecules disclosed herein may be transfected into a host cell of choice wherein the recombinant host cell provides a source for substantial levels of an expressed functional rhHER2/neu protein (SEQ ID NO:2 or SEQ ID NO:41).

The present invention further relates to an isolated nucleic acid molecule which encodes mRNA that expresses a novel rhesus monkey HER2/neu protein; this DNA molecule comprising the nucleotide sequence disclosed herein as SEQ ID NO:1. A preferred aspect of this portion of the present invention is disclosed in FIGURE 1, which shows a DNA molecule (SEQ ID NO:1) that encodes a novel rhHER2/neu protein (SEQ ID NO:2).

The present invention also provides an isolated nucleic acid molecule which encodes mRNA that expresses a novel rhesus monkey HER2/neu protein; this DNA molecule comprising the nucleotide sequence disclosed herein as SEQ ID NO:40. A preferred aspect of this portion of the present invention is disclosed in FIGURE 5, which shows a DNA molecule (SEQ ID NO:40) that encodes a novel rhHER2/neu protein (SEQ ID NO:41).

The present invention also relates to recombinant vectors and recombinant host cells, both prokaryotic and eukaryotic, which contain the nucleic acid molecules disclosed throughout this specification.

The present invention further relates to a process for expressing a rhesus monkey HER2/neu protein in a recombinant host cell, comprising: (a) introducing a vector comprising the nucleic acid as set forth in SEQ ID NO:1 or SEQ ID NO:40 into a suitable host cell; and, (b) culturing the host cell under conditions which allow expression of said rhesus monkey HER2/neu protein.

A preferred aspect of the present invention is a substantially purified form of a rhesus monkey HER2/neu protein which consists of the amino acid sequence disclosed in FIGURE 2 (SEQ ID NO:2).

A preferred aspect of the present invention is a substantially purified form of a rhesus monkey HER2/neu protein which consists of the amino acid sequence disclosed in FIGURE 6 (SEQ ID NO:41).

Yet another preferred aspect of the present invention relates to a substantially purified, fully processed (including proteolytic processing, glycosylation and/or phosphorylation), mature rhHER2/neu protein obtained from a recombinant host cell containing a DNA expression vector comprising nucleotide sequence as set forth in SEQ ID NO:1 or SEQ

ID NO:40, which express the rhHER2/neu protein. It is especially preferred that the recombinant host cell be a eukaryotic host cell, such as a mammalian cell line.

Another aspect of this invention is a method of preventing or treating cancer comprising administering to a mammal a vaccine vector comprising an isolated nucleic acid molecule, the isolated nucleic acid molecule comprising a sequence of nucleotides that encodes a rhesus monkey HER2/neu protein as set forth in SEQ ID NO:2 or SEQ ID NO:41.

The present invention further relates to an adenovirus vaccine vector comprising an adenoviral genome with a deletion in the E1 and E3 regions, and an insert in the E1 region, wherein the insert comprises an expression cassette comprising: (a) a polynucleotide encoding a rhesus monkey HER2/neu protein; and (b) a promoter operably linked to the polynucleotide.

The present invention also relates to a vaccine plasmid comprising a plasmid portion and an expression cassette portion, the expression cassette portion comprising: (a) a polynucleotide encoding a rhesus monkey HER2/neu protein; and (b) a promoter operably linked to the polynucleotide.

Another aspect of the present invention is a method of protecting or a mammal from cancer or treating a mammal suffering from cancer comprising: (a) introducing into the mammal a first vector comprising: i) a polynucleotide encoding a rhesus monkey HER2/neu protein; and ii) a promoter operably linked to the polynucleotide; (b) allowing a predetermined amount of time to pass; and (c) introducing into the mammal a second vector comprising: i) a polynucleotide encoding a rhesus monkey HER2/neu protein; and ii) a promoter operably linked to the polynucleotide.

As used throughout the specification and in the appended claims, the singular forms "a," "an," and "the" include the plural reference unless the context clearly dictates otherwise.

As used throughout the specification and appended claims, the following definitions and abbreviations apply:

The term "promoter" refers to a recognition site on a DNA strand to which the RNA polymerase binds. The promoter forms an initiation complex with RNA polymerase to initiate and drive transcriptional activity. The complex can be modified by activating sequences termed "enhancers" or inhibiting sequences termed "silencers".

The term "cassette" refers to the sequence of the present invention that contains the nucleic acid sequence which is to be expressed. The cassette is similar in concept to a cassette tape; each cassette has its own sequence. Thus by interchanging the cassette, the vector will express a different sequence. Because of the restriction sites at the 5' and 3' ends, the cassette can be easily inserted, removed or replaced with another cassette.

The term "vector" refers to some means by which DNA fragments can be introduced into a host organism or host tissue. There are various types of vectors including plasmid, virus (including adenovirus), bacteriophages and cosmids.

The term "first generation," as used in reference to adenoviral vectors, describes said adenoviral vectors that are replication-defective. First generation adenovirus vectors typically have a deleted or inactivated E1 gene region, and preferably have a deleted or inactivated E3 gene region.

The designation "pMRKAd5-rhHER2/neu" refers to a plasmid construct, disclosed herein, which comprises an Ad5 adenoviral genome deleted of the E1 and E3 regions. In this plasmid, the E1 region is replaced by a rhesus HER2/neu gene in an E1 parallel orientation, under the control of a human CMV promoter without intron A, followed by a bovine growth hormone polyadenylation signal.

The designation "MRKAd5-rhHER2/neu" refers to the virus generated from plasmid pMRKAD5-rhHER2/neu following removal of plasmid sequences by restriction and transfection into an E1-expressing cell line, such as Per.C6 or HEK 293.

The designation "pV1J-rhHER2/neu" refers to a plasmid construct disclosed herein comprising the human CMV immediate-early (IE) promoter and intron A, a full-length rhesus HER2/neu gene, a bovine growth hormone-derived polyadenylation and transcriptional termination sequences, and a minimal pUC backbone.

The term "first rhesus HER2/neu DNA sequence," as used interchangeably with the term "rhHER2#1," refers to the rhesus HER2/neu sequence as identified and isolated herein in EXAMPLE 1 and set forth in SEQ ID NO:1. This sequence was translated to determine the amino acid sequence of the "first rhesus HER2/neu protein," as set forth in SEQ ID NO:2.

The term "second rhesus HER2/neu DNA sequence," as used interchangeably with the term "rhHER2#2," refers to the rhesus HER2/neu sequence as identified and isolated herein in EXAMPLE 4 and set forth in SEQ ID NO:40. This DNA molecule was isolated from a different rhesus monkey than the DNA molecule described in EXAMPLE 1. This sequence was translated to deduce the amino acid sequence of the "second rhesus HER2/neu protein," as set forth in SEQ ID NO:41. Differences between the rhHER2#1 and rhHER2#2 nucleotide and amino acid sequences are detailed in FIGURE 7.

The term "effective amount" means sufficient vaccine composition is introduced to produce the adequate levels of the polypeptide, so that an immune response results. One skilled in the art recognizes that this level may vary.

"Substantially free from other nucleic acids" means at least 90%, preferably 95%, more preferably 99%, and even more preferably 99.9%, free of other nucleic acids. As used

interchangeably, the terms "substantially free from other nucleic acids," "substantially purified," "isolated nucleic acid" or "purified nucleic acid" also refer to DNA molecules which comprise a coding region for a rhesus HER2/neu protein that has been purified away from other cellular components. Thus, a rhesus HER2/neu DNA preparation that is substantially free from other nucleic acids will contain, as a percent of its total nucleic acid, no more than 10%, preferably no more than 5%, more preferably no more than 1%, and even more preferably no more than 0.1%, of non-rhesus HER2/neu nucleic acids. Whether a given rhesus HER2/neu DNA preparation is substantially free from other nucleic acids can be determined by such conventional techniques of assessing nucleic acid purity as, e.g., agarose gel electrophoresis combined with appropriate staining methods, e.g., ethidium bromide staining, or by sequencing.

"Substantially free from other proteins" or "substantially purified" means at least 90%, preferably 95%, more preferably 99%, and even more preferably 99.9%, free of other proteins. Thus, a rhesus monkey HER2/neu protein preparation that is substantially free from other proteins will contain, as a percent of its total protein, no more than 10%, preferably no more than 5%, more preferably no more than 1%, and even more preferably no more than 0.1%, of non-rhesus monkey HER2/neu proteins. Whether a given rhesus monkey HER2/neu protein preparation is substantially free from other proteins can be determined by such conventional techniques of assessing protein purity as, e.g., sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) combined with appropriate detection methods, e.g., silver staining or immunoblotting.

As used interchangeably, the terms "substantially free from other proteins" or "substantially purified," or "isolated rhesus monkey HER2/neu protein" or "purified rhesus monkey HER2/neu protein" also refer to rhesus monkey HER2/neu protein that has been isolated from a natural source. Use of the term "isolated" or "purified" indicates that rhesus monkey HER2/neu protein has been removed from its normal cellular environment. Thus, an isolated rhesus monkey HER2/neu protein may be in a cell-free solution or placed in a different cellular environment from that in which it occurs naturally. The term isolated does not imply that an isolated rhesus monkey HER2/neu protein is the only protein present, but instead means that an isolated rhHER2/neu protein is substantially free of other proteins and non-amino acid material (e.g., nucleic acids, lipids, carbohydrates) naturally associated with the rhHER2/neu protein *in vivo*. Thus, a rhesus monkey HER2/neu protein that is recombinantly expressed in a prokaryotic or eukaryotic cell and substantially purified from this host cell which does not naturally (*i.e.*, without intervention) express this rhHER2/neu protein is of course "isolated rhesus monkey HER2/neu protein" under any circumstances referred to herein. As noted above, a rhHER2/neu protein preparation that is an isolated or purified rhHER2/neu protein will be

substantially free from other proteins and will contain, as a percent of its total protein, no more than 10%, preferably no more than 5%, more preferably no more than 1%, and even more preferably no more than 0.1%, of non-rhesus monkey HER2/neu proteins.

A "conservative amino acid substitution" refers to the replacement of one amino acid residue by another, chemically similar, amino acid residue. Examples of such conservative substitutions are: substitution of one hydrophobic residue (isoleucine, leucine, valine, or methionine) for another; substitution of one polar residue for another polar residue of the same charge (e.g., arginine for lysine; glutamic acid for aspartic acid).

The term "mammalian" refers to any mammal, including a human being.

The abbreviation "Ag" refers to an antigen.

The abbreviations "Ab" and "mAb" refer to an antibody and a monoclonal antibody, respectively.

#### BRIEF DESCRIPTION OF THE DRAWINGS

FIGURE 1 shows the nucleotide sequence of the first rhesus monkey HER2/neu cDNA, as set forth in SEQ ID NO:1 (see EXAMPLE 1). The presence of an "R" at position 795 indicates that either an A or a G is located at that position.

FIGURE 2 shows the predicted amino acid sequence of rhesus monkey HER2/neu protein, as set forth in SEQ ID NO:2. The amino acid sequence shown was deduced from the nucleotide sequence disclosed as SEQ ID NO:1.

FIGURE 3 discloses the nucleotide sequences of oligonucleotide primers spanning the HER2/neu gene, which were used to generate a series of rhesus HER2/neu fragments by RT-PCR (see EXAMPLE 1). Columns marked "Forward" and "Reverse" state the location of the primers with respect to the published human HER2/neu sequence (Accession M11730). Primers disclosed as SEQ ID NOs: 15 and 16 were designed to mutate amino acid position 579 from K to A, to inactivate the tyrosine kinase activity of the translated protein. Primers 3388-3410 and 3410-3388 have a sequence with a C at position 15 and a G at position 10, respectively, which code for Ser (AGC). In contrast, the Rhesus HER2/neu sequence has a T at that position, coding again for Ser (AGT). These primers were used for sequencing, but not for cloning purposes. For SEQ ID NOs: 11 and 19, sequence priming on rhHER2/neu is underlined.

FIGURE 4 shows the sequences of RT-PCR primers used to construct the full-length rhesus HER2/neu clone (see EXAMPLE 2). The first column lists the reaction number corresponding to the reactions discussed in EXAMPLE 2. Each row depicts a set of forward and reverse primers used to generate the clones listed in column 4. Nomenclature for the clones

indicates both the vector used for cloning (BS or CR for pBluescript or pCRII, respectively) and the location of the sequence relative to the published human HER2/neu sequence (listed as numbers).

FIGURE 5 shows the nucleotide sequence of the second rhesus monkey HER2/neu cDNA, as set forth in SEQ ID NO:40 (see EXAMPLE 4). The presence of an "R" within the nucleotide sequence indicates that either an "A" or a "G" is located at that position. The presence of a "Y" within the sequence indicates that a "C" or a "T" is located at that position. Nucleotide bases that are different from the corresponding bases of the first rhesus HER2/neu (SEQ ID NO:1) are bold and underlined.

FIGURE 6 shows the predicted amino acid sequence of the second rhesus monkey HER2/neu protein, as set forth in SEQ ID NO:41 (see EXAMPLE 4). The amino acid sequence shown was deduced from the nucleotide sequence disclosed as SEQ ID NO:40. The "X" at position 517 indicates that a "Q" (Gln) or an "R" (Arg) may be present at that position. The "X" at position 647 indicates that a "K" (Lys) or an "R" (Arg) may be present at that position. The "X" at position 1075 indicates that an "R" (Arg) or a "Q" (Gln) may be present at that position.

FIGURE 7 details the specific mutations present in the second rhesus HER2/neu DNA and protein sequences (RhHER2#2, SEQ ID NOs:40 and 41 ) as compared to the first rhesus HER2/neu DNA and protein sequences (RhHER2#1, SEQ ID NOs: 1 and 2). The first column in each table lists the position of nucleotides that are different between RhHER2#2 and RhHER2#1. The second column in each table list the number of specific clones carrying HER2/neu fragments that were isolated and used to determine the sequence of RhHER2#1 and RhHER2#2, respectively. The third column in each table shows the sequence of the codon in which the differences occur, with dissimilar nucleotides highlighted. Below the codons are the one-letter amino acid symbols for the resulting amino acids, highlighted in gray.

#### DETAILED DESCRIPTION OF THE INVENTION

The gene encoding the HER2/neu tumor-associated antigen is commonly associated with the development of epithelial-derived human carcinomas. The present invention relates to compositions and methods to elicit or enhance immunity to the protein product expressed by the HER2/neu tumor-associated antigen, wherein aberrant HER2/neu expression is associated with the carcinoma or its development. Association of aberrant HER2/neu expression with a carcinoma does not require that the HER2/neu protein be expressed in tumor tissue at all timepoints of its development, as abnormal HER2/neu expression may be present at tumor initiation and not be detectable late into tumor progression.

To this end, polynucleotides encoding rhesus monkey HER2/neu are provided. The molecules of the present invention may be used in a recombinant adenovirus vaccine to provide effective immunoprophylaxis against epithelial-derived carcinomas through cell-mediated immunity. When directly introduced into a vertebrate *in vivo*, the invention polynucleotides induce the expression of encoded proteins within the animal, including mammals such as primates, dogs and humans.

The present invention relates to an isolated nucleic acid molecule (polynucleotide) comprising a sequence of nucleotides which encodes mRNA that expresses a novel rhHER2/neu protein as set forth in SEQ ID NO:2. The present invention also relates to an isolated nucleic acid molecule comprising a sequence of nucleotides which encodes mRNA that expresses a novel rhHER2/neu protein as set forth in SEQ ID NO:41. The nucleic acid molecules of the present invention are substantially free from other nucleic acids.

The isolated nucleic acid molecules of the present invention may include a deoxyribonucleic acid molecule (DNA), such as genomic DNA and complementary DNA (cDNA), which may be single (coding or noncoding strand) or double stranded, as well as synthetic DNA, such as a synthesized, single stranded polynucleotide. The isolated nucleic acid molecules of the present invention may also include a ribonucleic acid molecule (RNA). For most cloning purposes, DNA is a preferred nucleic acid.

A preferred DNA molecule of the present invention comprises the nucleotide sequence disclosed herein as SEQ ID NO:1, shown in FIGURE 1, which encodes the rhesus HER2/neu protein shown in FIGURE 2 and set forth as SEQ ID NO:2. This rhHER2/neu nucleic acid molecule was identified through RT-PCR as described in detail in EXAMPLE 1. The presence of an "R" at position 795 of SEQ ID NO:1 indicates that clones isolated from the first rhesus monkey comprised either an A or a G at that position. A nucleic acid molecule isolated from the first rhesus monkey and comprising an "A" at position 795 is designated herein SEQ ID NO:42. A nucleic acid molecule isolated from the first rhesus monkey and comprising a "G" at position 795 is designated herein SEQ ID NO:43.

A second preferred DNA molecule comprises the nucleotide sequence disclosed herein as SEQ ID NO:40, shown in FIGURE 5, which encodes the rhesus HER2/neu protein shown in FIGURE 6 and set forth as SEQ ID NO:41. The isolated cDNA clones, associated vectors, hosts, recombinant subcellular fractions and membranes, and the expressed and mature forms of rhHER2/neu are useful for the development of a cancer vaccine.

The present invention also includes biologically active fragments or mutants of SEQ ID NO:1 or SEQ ID NO:40, which encode mRNA expressing novel rhHER2/neu proteins. Any such biologically active fragment and/or mutant will encode either a protein or protein

fragment which at least substantially mimics the pharmacological properties of the rhHER2/neu protein, including but not limited to the rhHER2/neu proteins as set forth in SEQ ID NO:2 and SEQ ID NO:41. Any such polynucleotide includes but is not necessarily limited to: nucleotide substitutions, deletions, additions, amino-terminal truncations and carboxy-terminal truncations. The mutations of the present invention encode mRNA molecules that express a functional rhHER2/neu protein in a eukaryotic cell so as to be useful in cancer vaccine development.

This invention also relates to synthetic DNA that encodes the rhHER2/neu protein where the nucleotide sequence of the synthetic DNA differs significantly from the nucleotide sequence of SEQ ID NO:1 and SEQ ID NO:40, but still encodes the same rhHER2/neu protein as SEQ ID NO:2 or SEQ ID NO:41. Such synthetic DNAs are intended to be within the scope of the present invention.

Therefore, the present invention discloses codon redundancy that may result in numerous DNA molecules expressing an identical protein. For purposes of this specification, a sequence bearing one or more replaced codons will be defined as a degenerate variation. Also included within the scope of this invention are mutations either in the DNA sequence or the translated protein that do not substantially alter the ultimate physical properties of the expressed protein. For example, substitution of valine for leucine, arginine for lysine, or asparagine for glutamine may not cause a change in the functionality of the polypeptide.

It is known that DNA sequences coding for a peptide may be altered so as to code for a peptide that has properties that are different than those of the naturally occurring peptide. Methods of altering the DNA sequences include but are not limited to site directed mutagenesis. Examples of altered properties include but are not limited to changes in the affinity of an enzyme for a substrate or receptor for a ligand.

Included in the present invention are DNA sequences that hybridize to SEQ ID NO:1 or SEQ ID NO:40 under stringent conditions. By way of example, and not limitation, a procedure using conditions of high stringency is as follows: Prehybridization of filters containing DNA is carried out for 2 hours to overnight at 65°C in buffer composed of 6X SSC, 5X Denhardt's solution, and 100 µg/ml denatured salmon sperm DNA. Filters are hybridized for 12 to 48 hrs at 65°C in prehybridization mixture containing 100 µg/ml denatured salmon sperm DNA and 5-20 X 10<sup>6</sup> cpm of <sup>32</sup>P-labeled probe. Washing of filters is done at 37°C for 1 hr in a solution containing 2X SSC, 0.1% SDS. This is followed by a wash in 0.1X SSC, 0.1% SDS at 50°C for 45 min. before autoradiography. Other procedures using conditions of high stringency would include either a hybridization step carried out in 5XSSC, 5X Denhardt's solution, 50% formamide at 42°C for 12 to 48 hours or a washing step carried out in 0.2X SSPE, 0.2% SDS at 65°C for 30 to 60 minutes.

Reagents mentioned in the foregoing procedures for carrying out high stringency hybridization are well known in the art. Details of the composition of these reagents can be found in, e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual*; Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1989 which is hereby incorporated by reference. In addition to the foregoing, other conditions of high stringency which may be used are well known in the art.

A preferred aspect of the present invention is a substantially purified form of a rhesus monkey HER2/neu protein which comprises a sequence of amino acids as disclosed in FIGURE 2 (SEQ ID NO:2).

Another preferred aspect of the present invention is a substantially purified form of a rhesus monkey HER2/neu protein which comprises a sequence of amino acids as disclosed in FIGURE 6 (SEQ ID NO:41).

This invention also relates to various functional domains of rhHER2/neu, such as the extracellular domain and the intracellular domain, and to hybrid molecules comprising at least one of these sequences.

The present invention also includes biologically active fragments and/or mutants of a rhHER2/neu protein, comprising the amino acid sequence as set forth in SEQ ID NO: 2 or SEQ ID NO:41, including but not necessarily limited to amino acid substitutions, deletions, additions, amino terminal truncations and carboxy-terminal truncations such that these mutations provide for proteins or protein fragments of diagnostic, therapeutic or prophylactic use and would be useful for cancer vaccine development.

The rhesus monkey HER2/neu proteins of the present invention may be in the form of the "mature" protein or may be a part of a larger protein such as a fusion protein. It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification such as multiple histidine residues, or an additional sequence for stability during recombinant production.

The present invention also relates to rhHER2/neu fusion constructs, including but not limited to fusion constructs which express a portion of the rhesus HER2/neu protein linked to various markers, including but in no way limited to GFP (Green fluorescent protein), the MYC epitope, GST, and Fc. Any such fusion construct may be expressed in the cell line of interest and used to screen for modulators of the rhesus HER2/neu protein disclosed herein.

The present invention further relates to recombinant vectors that comprise the substantially purified nucleic acid molecules disclosed throughout this specification. These vectors may be comprised of DNA or RNA. For most cloning purposes, DNA vectors are preferred. Typical vectors include plasmids, modified viruses, bacteriophage, cosmids, yeast

artificial chromosomes, and other forms of episomal or integrated DNA that can encode a rhHER2/neu protein. It is well within the purview of the skilled artisan to determine an appropriate vector for a particular gene transfer or other use.

An expression vector containing DNA encoding a rhHER2/neu protein may be used for expression of rhHER2/neu in a recombinant host cell. Expression vectors may include, but are not limited to, cloning vectors, modified cloning vectors, specifically designed plasmids or viruses. Also, a variety of bacterial expression vectors may be used to express recombinant rhHER2/neu in bacterial cells if desired. In addition, a variety of fungal cell expression vectors may be used to express recombinant rhHER2/neu in fungal cells. Further, a variety of insect cell expression vectors may be used to express recombinant protein in insect cells.

The present invention also relates to host cells transformed or transfected with vectors comprising the nucleic acid molecules of the present invention. Recombinant host cells may be prokaryotic or eukaryotic, including but not limited to, bacteria such as *E. coli*, fungal cells such as yeast, mammalian cells including, but not limited to, cell lines of bovine, porcine, monkey and rodent origin; and insect cells including but not limited to *Drosophila* and silkworm derived cell lines. Such recombinant host cells can be cultured under suitable conditions to produce rhHER2/neu or a biologically equivalent form.

As noted above, an expression vector containing DNA encoding a rhHER2/neu protein may be used for expression of rhHER2/neu in a recombinant host cell. Therefore, another aspect of this invention is a process for expressing a rhesus monkey HER2/neu protein in a recombinant host cell, comprising: (a) introducing a vector comprising the nucleic acid of as set forth in SEQ ID NO:1 or SEQ ID NO:40 into a suitable host cell; and, (b) culturing the host cell under conditions which allow expression of said rhesus monkey HER2/neu protein.

Following expression of rhHER2/neu in a host cell, rhHER2/neu protein may be recovered to provide rhHER2/neu protein in active form. Several rhHER2/neu protein purification procedures are available and suitable for use. Recombinant rhHER2/neu protein may be purified from cell lysates and extracts by various combinations of, or individual application of salt fractionation, ion exchange chromatography, size exclusion chromatography, hydroxylapatite adsorption chromatography and hydrophobic interaction chromatography. In addition, recombinant rhHER2/neu protein can be separated from other cellular proteins by use of an immunoaffinity column made with monoclonal or polyclonal antibodies specific for full-length rhHER2/neu protein, or polypeptide fragments of rhHER2/neu protein.

The nucleic acids of the present invention may be assembled into an expression cassette that comprises sequences designed to provide for efficient expression of the protein in a human cell. The cassette preferably contains the full-length rhHER2/neu gene, with related

transcriptional and translations control sequences operatively linked to it, such as a promoter, and termination sequences. In a preferred embodiment, the promoter is the cytomegalovirus promoter without the intron A sequence, although those skilled in the art will recognize that any of a number of other known promoters such as the strong immunoglobulin, or other eukaryotic gene promoters may be used. A preferred transcriptional terminator is the bovine growth hormone terminator, although other known transcriptional terminators may also be used. The combination of CMV-BGH terminator is particularly preferred.

In accordance with this invention, the rhesus HER2/neu expression cassette is inserted into a vector. The vector is preferably an adenoviral vector, although linear DNA linked to a promoter, or other vectors, such as adeno-associated virus or a modified vaccinia virus vector may also be used.

If the vector chosen is an adenovirus, it is preferred that the vector be a so-called first-generation adenoviral vector. These adenoviral vectors are characterized by having a non-functional E1 gene region, and preferably a deleted adenoviral E1 gene region. In some embodiments, the expression cassette is inserted in the position where the adenoviral E1 gene is normally located. In addition, these vectors optionally have a non-functional or deleted E3 region. It is preferred that the adenovirus genome used be deleted of both the E1 and E3 regions ( $\Delta E1\Delta E3$ ). The adenoviruses can be multiplied in known cell lines which express the viral E1 gene, such as 293 cells, or PERC.6 cells, or in cell lines derived from 293 or PERC.6 cell which are transiently or stably transformed to express an extra protein. For examples, when using constructs that have a controlled gene expression, such as a tetracycline regulatable promoter system, the cell line may express components involved in the regulatory system. One example of such a cell line is T-Rex-293; others are known in the art.

For convenience in manipulating the adenoviral vector, the adenovirus may be in a shuttle plasmid form. This invention is also directed to a shuttle plasmid vector which comprises a plasmid portion and an adenovirus portion, the adenovirus portion comprising an adenoviral genome which has a deleted E1 and optional E3 deletion, and has an inserted expression cassette comprising rhesus HER2/neu. In preferred embodiments, there is a restriction site flanking the adenoviral portion of the plasmid so that the adenoviral vector can easily be removed. The shuttle plasmid may be replicated in prokaryotic cells or eukaryotic cells.

In a preferred embodiment of the invention, the expression cassette is inserted into the pMRKAd5-HV0 adenovirus plasmid (See Emini et al., WO 02/22080, which is hereby incorporated by reference). This plasmid comprises an Ad5 adenoviral genome deleted of the E1 and E3 regions. The design of the pMRKAd5-HV0 plasmid was improved over prior

adenovectors by extending the 5' cis-acting packaging region further into the E1 gene to incorporate elements found to be important in optimizing viral packaging, resulting in enhanced virus amplification. Advantageously, this enhanced adenoviral vector is capable of maintaining genetic stability following high passage propagation.

Standard techniques of molecular biology for preparing and purifying DNA constructs enable the preparation of the adenoviruses, shuttle plasmids, and DNA immunogens of this invention.

The vectors described above may be used in immunogenic compositions and vaccines for preventing the development of epithelial-derived carcinomas associated with aberrant HER2/neu expression and/or for treating existing cancers. To this end, one aspect of the instant invention is a method of preventing or treating cancer comprising administering to a mammal a vaccine vector comprising an isolated nucleic acid molecule, the isolated nucleic acid molecule comprising a sequence of nucleotides that encodes a rhesus monkey HER2/neu protein as set forth in SEQ ID NO:2 or SEQ ID NO:41.

In accordance with the method described above, the vaccine vector may be administered for the treatment or prevention of cancer in any mammal. In a preferred embodiment of the invention, the mammal is a human.

Further, one of skill in the art may choose any type of vector for use in the treatment and prevention method described. Preferably, the vector is an adenovirus vector or a plasmid vector. In a preferred embodiment of the invention, the vector is an adenoviral vector comprising an adenoviral genome with a deletion in the adenovirus E1 region, and an insert in the adenovirus E1 region, wherein the insert comprises an expression cassette comprising: (a) a polynucleotide encoding a rhesus monkey HER2/neu protein; and (b) a promoter operably linked to the polynucleotide.

The instant invention further relates to an adenovirus vaccine vector comprising an adenoviral genome with a deletion in the E1 region, and an insert in the E1 region, wherein the insert comprises an expression cassette comprising: (a) a polynucleotide encoding a rhesus monkey HER2/neu protein; and (b) a promoter operably linked to the polynucleotide.

In a preferred embodiment of this aspect of the invention, the adenovirus vector is an Ad 5 vector.

In another aspect, the invention relates to a vaccine plasmid comprising a plasmid portion and an expression cassette portion, the expression cassette portion comprising: (a) a polynucleotide encoding a rhesus monkey HER2/neu protein; and (b) a promoter operably linked to the polynucleotide.

In some embodiments of this invention, the recombinant adenovirus vaccines disclosed herein are used in various prime/boost combinations with a plasmid-based polynucleotide vaccine in order to induce an enhanced immune response. In this case, the two vectors are administered in a "prime and boost" regimen. For example the first type of vector is administered, then after a predetermined amount of time, for example, 1 month, 2 months, six months, or other appropriate interval, a second type of vector is administered. Preferably the vectors carry expression cassettes encoding the same polynucleotide or combination of polynucleotides. In the embodiment where a plasmid DNA is also used, it is preferred that the vector contain one or more promoters recognized by mammalian or insect cells. In a preferred embodiment, the plasmid would contain a strong promoter such as, but not limited to, the human CMV promoter. The rhesus HER2/neu gene or other gene to be expressed would be linked to such a promoter. An example of such a plasmid would be the mammalian expression plasmid V1Jns as described (J. Shiver et. al. *in DNA Vaccines*, M. Liu et al. eds., N.Y. Acad. Sci., N.Y., 772:198-208 (1996), which is herein incorporated by reference).

As stated above, an adenoviral vector vaccine and a plasmid vaccine may be administered to a vertebrate as part of a single therapeutic regime to induce an immune response. To this end, the present invention relates to a method of protecting a mammal from cancer comprising: (a) introducing into the mammal a first vector comprising: i) a polynucleotide encoding a rhesus monkey HER2/neu protein; and ii) a promoter operably linked to the polynucleotide; (b) allowing a predetermined amount of time to pass; and (c) introducing into the mammal a second vector comprising: i) a polynucleotide encoding a rhesus monkey HER2/neu protein; and ii) a promoter operably linked to the polynucleotide.

In one embodiment of the method of protection described above, the first vector is a plasmid and the second vector is an adenovirus vector. In an alternative embodiment, the first vector is an adenovirus vector and the second vector is a plasmid.

The instant invention further relates to a method of treating a mammal suffering from an epithelial-derived carcinoma comprising: (a) introducing into the mammal a first vector comprising: i) a polynucleotide encoding a rhesus monkey HER2/neu protein; and ii) a promoter operably linked to the polynucleotide; (b) allowing a predetermined amount of time to pass; and (c) introducing into the mammal a second vector comprising: i) a polynucleotide encoding a rhesus monkey HER2/neu protein; and ii) a promoter operably linked to the polynucleotide.

In one embodiment of the method of treatment described above, the first vector is a plasmid and the second vector is an adenovirus vector. In an alternative embodiment, the first vector is an adenovirus vector and the second vector is a plasmid.

The amount of expressible DNA or transcribed RNA to be introduced into a vaccine recipient will depend partially on the strength of the promoters used and on the immunogenicity of the expressed gene product. In general, an immunologically or prophylactically effective dose of about 1 ng to 100 mg, and preferably about 10 $\mu$ g to 300  $\mu$ g of a plasmid vaccine vector is administered directly into muscle tissue. An effective dose for recombinant adenovirus is approximately 10<sup>6</sup> – 10<sup>12</sup> particles and preferably about 10<sup>7</sup>—10<sup>11</sup> particles. Subcutaneous injection, intradermal introduction, impression through the skin, and other modes of administration such as intraperitoneal, intravenous, or inhalation delivery are also contemplated. It is also contemplated that booster vaccinations may be provided. Parenteral administration, such as intravenous, intramuscular, subcutaneous or other means of administration with adjuvants such as interleukin 12 protein, concurrently with or subsequent to parenteral introduction of the vaccine of this invention is also advantageous.

The vaccine vectors of this invention may be naked, i.e., unassociated with any proteins, adjuvants or other agents which impact on the recipient's immune system. In this case, it is desirable for the vaccine vectors to be in a physiologically acceptable solution, such as, but not limited to, sterile saline or sterile buffered saline. Alternatively, it may be advantageous to administer an immunostimulant, such as an adjuvant, cytokine, protein, or other carrier with the vaccines or immunogenic compositions of the present invention. Therefore, this invention includes the use of such immunostimulants in conjunction with the compositions and methods of the present invention. An immunostimulant, as used herein, refers to essentially any substance that enhances or potentiates an immune response (antibody and/or cell-mediated) to an exogenous antigen. Said immunostimulants can be administered in the form of DNA or protein. Any of a variety of immunostimulants may be employed in conjunction with the vaccines and immunogenic compositions of the present inventions, including, but not limited to: GM-CSF, IFN $\alpha$ , tetanus toxoid, IL12, B7.1, LFA-3 and ICAM-1. Said immunostimulants are well-known in the art. Agents which assist in the cellular uptake of DNA, such as, but not limited to calcium ion, may also be used. These agents are generally referred to as transfection facilitating reagents and pharmaceutically acceptable carriers. Those of skill in the art will be able to determine the particular immunostimulant or pharmaceutically acceptable carrier as well as the appropriate time and mode of administration.

Any of a variety of procedures may be used to clone rhHER2/neu. These methods include, but are not limited to, (1) a RACE PCR cloning technique (Frohman et al., *Proc. Natl. Acad. Sci. USA* 85: 8998-9002 (1988)). 5' and/or 3' RACE may be performed to generate a full-length cDNA sequence. This strategy involves using gene-specific oligonucleotide primers for PCR amplification of rhHER2/neu cDNA. These gene-specific

primers are designed through identification of an expressed sequence tag (EST) nucleotide sequence which has been identified by searching any number of publicly available nucleic acid and protein databases; (2) direct functional expression of the rhHER2/neu cDNA following the construction of a rhHER2/neu-containing cDNA library in an appropriate expression vector system; (3) screening an rhHER2/neu-containing cDNA library constructed in a bacteriophage or plasmid shuttle vector with a labeled degenerate oligonucleotide probe designed from the amino acid sequence of the rHER2/neu protein; (4) screening an rhHER2/neu-containing cDNA library constructed in a bacteriophage or plasmid shuttle vector with a partial cDNA encoding the rhHER2/neu protein. This partial cDNA is obtained by the specific PCR amplification of rhHER2/neu DNA fragments through the design of degenerate oligonucleotide primers from the amino acid sequence known for other growth factor receptors which are related to the rhHER2/neu protein; (5) screening a rhHER2/neu-containing cDNA library constructed in a bacteriophage or plasmid shuttle vector with a partial cDNA or oligonucleotide with homology to a mammalian rhHER2/neu protein. This strategy may also involve using gene-specific oligonucleotide primers for PCR amplification of rhHER2/neu cDNA identified as an EST as described above; or (6) designing 5' and 3' gene specific oligonucleotides using SEQ ID NO: 1 or SEQ ID NO:40 as a template so that either the full-length cDNA may be generated by known RACE techniques, or a portion of the coding region may be generated by these same known RACE techniques to generate and isolate a portion of the coding region to use as a probe to screen one of numerous types of cDNA and/or genomic libraries in order to isolate a full-length version of the nucleotide sequence encoding rhHER2/neu.

It is readily apparent to those skilled in the art that other types of libraries, as well as libraries constructed from other cell types-or species types, may be useful for isolating a rhHER2/neu-encoding DNA or a rhHER2/neu homologue. Other types of libraries include, but are not limited to, cDNA libraries derived from other cells.

It is also readily apparent to those skilled in the art that suitable cDNA libraries may be prepared from cells or cell lines which have rhHER2/neu activity, such as various epithelial-derived cells. The selection of cells or cell lines for use in preparing a cDNA library to isolate a cDNA encoding rhHER2/neu may be done by first measuring cell-associated rhHER2/neu activity using any known assay available for such a purpose.

Preparation of cDNA libraries can be performed by standard techniques well known in the art. Well known cDNA library construction techniques can be found for example, in Sambrook et al., *Molecular Cloning: A Laboratory Manual*; Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1989. Complementary DNA libraries may also be obtained

from numerous commercial sources, including but not limited to Clontech Laboratories, Inc. (Palo Alto, CA) and Stratagene (La Jolla, CA).

The DNA molecules, RNA molecules, and recombinant protein of the present invention may be used to screen and measure levels of rhHER2/neu. The recombinant proteins, DNA molecules, and RNA molecules lend themselves to the formulation of kits suitable for the detection and typing of rhHER2/neu. Such a kit would comprise a compartmentalized carrier suitable to hold in close confinement at least one container. The carrier would further comprise reagents such as recombinant rhHER2/neu or anti-rhHER2/neu antibodies suitable for detecting rhHER2/neu. The carrier may also contain a means for detection such as labeled antigen or enzyme substrates or the like.

All publications mentioned herein are incorporated by reference for the purpose of describing and disclosing methodologies and materials that might be used in connection with the present invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

Having described preferred embodiments of the invention with reference to the accompanying drawings, it is to be understood that the invention is not limited to those precise embodiments, and that various changes and modifications may be effected therein by one skilled in the art without departing from the scope or spirit of the invention as defined in the appended claims.

The following examples illustrate, but do not limit the invention.

#### EXAMPLE 1

##### Isolation of the Rhesus HER2/neu cDNA by RT-PCR

Molecular procedures were performed following standard procedures well known in the art (See; e.g., Ausubel et. al. *Short Protocols in Molecular Biology*, F.M., -2nd. ed., John Wiley & Sons, (1992) and Sambrook et al., *Molecular Cloning, A Laboratory Manual*, 2nd ed., Cold Spring Harbor Laboratory Press (1989), which are hereby incorporated by reference).

HER2/neu nucleotide sequences from human, hamster, dog, and rat were aligned to identify highly conserved regions of the HER2/neu DNA. Based on the sequence comparison, oligonucleotide primers spanning the HER2/neu gene were designed for amplification of the rhesus HER2/neu cDNA by reverse transcriptase polymerase chain reaction (RT-PCR), described below. (see FIGURE 3).

Colon biopsies from two different Rhesus monkeys (*macaca mulatta*) were obtained from Dr. Willem Collignon (Biomedical Primate Research Centre (BPRC), Rijswijk, The Netherlands). RNA was extracted and purified from each colon biopsy using the UltraSPec-

II RNA isolation system (Biotecx, Houston, TX) according to the manufacturer's instructions. To isolate the rhesus HER2/neu gene, RT-PCR amplification products covering the entire HER2/neu sequence were generated from total RNA isolated from a single rhesus monkey.

To perform the reverse transcription step, total RNA samples were reverse transcribed using the Superscript One-Step RT-PCR Amplification Kit for Long Templates (Life Technologies; Carlsbad, CA) according to the manufacturer's instructions. Typically, 0.5-2.0 µg RNA were combined with the reverse transcriptase enzyme and the appropriate buffer in a 50µl reaction volume. Samples were incubated at 45 °C for 30 min, followed by a 2 minute incubation at 94 °C.

Using the resulting cDNA templates, PCR amplifications were performed using different combinations of forward and reverse primers (see FIGURE 3). PCR was carried out in a Perkin Elmer 2400 thermocycler (Perkin Elmer, Inc., Wellesley, MA). Cycling conditions consisted of 35 cycles of an initial denaturation step of 94°C for 15 sec, followed by a primer annealing step and concluding with an extension step. The primer annealing step consisted of incubation for 50 sec at a temperature ranging from (50°C -51°C), depending on the primer sequence. The extension step consisted of an incubation at 68°C for a length of time ranging from (80 sec-100 sec), depending on the expected length of the amplification product. The above 35 cycles were followed by an extensive elongation step of 7 min at 72°C.

Amplification products were gel-purified using the QIAquick PCR Purification Kit (Qiagen, Hilden, Germany) and sequenced with the same primers used for amplification. Sequencing reactions were carried out through Big Dye Terminator chemistry, using the Cycle Sequencing Ready Reaction Kit (Applied Biosystems, Foster City, CA). Readings were performed using an ABI Prism 377 DNA sequencer (Applied Biosystem).

Data acquired by sequencing the different amplification products, which encompass the entire HER2/neu coding region, identified the rhesus HER2/neu sequence, disclosed herein as SEQ ID NO:1 (hereinafter "first rhesus HER2 nucleotide sequence" or "rhHER2#1," see FIGURE 1). The presence of an "R" at position 795 of SEQ ID NO:1 indicates that clones isolated from the first rhesus monkey comprised either an A or a G at that position. A nucleic acid molecule isolated from the first rhesus monkey and comprising an "A" at position 795 is designated herein SEQ ID NO:42. A nucleic acid molecule isolated from the first rhesus monkey and comprising a "G" at position 795 is designated herein SEQ ID NO:43. The single nucleotide change at position 795 of SEQ ID NO:1, based on DNA isolated from the first rhesus monkey, did not affect the resulting amino acid sequence of the HER2/neu protein, which is disclosed herein as SEQ ID NO:2 (see FIGURE 2).

Amplification products derived from the above RT-PCR reactions were cloned into either vector BlueScript ks(+) or pCRII, referred to herein as BS or CR, respectively. The resulting clones were sequenced to confirm the rhHER2/neu nucleotide sequence obtained by direct sequencing of amplification products and used to assemble the complete rhesus HER2/neu cDNA sequence.

## EXAMPLE 2

### Assembly of the Complete HER2/neu cDNA Sequence

A series of clones obtained from the first rhesus monkey were constructed and assembled by PCR to generate the complete rhesus HER2/neu cDNA. First, four RT-PCR amplification products spanning the 5' end of the rhesus HER2/neu gene were generated as described in EXAMPLE 1. The PCR - amplified fragments from the above clones were cloned into either BS or CR, as indicated in FIGURE 4 (Reactions 1-4). Sequence analysis of several clones confirmed that the cloned sequences were the same as sequences obtained from the RT-PCR fragments.

The overlapping amplication products described above were ligated in a 100 $\mu$ l PCR reaction in which the following components were combined: 0.1-1.0 pmol of each of the above fragments, Pfu polymerase (Stratagene, La Jolla, CA) and the appropriate buffer. Samples were subjected to an initial amplification cycle consisting of 30 sec at 95°C, followed by 4 min at 72°C.

The resulting ligation product was amplified again with the PmeI\_SwaI\_RBS\_1-16 (SEQ ID NO:11) and 1895-1876 (SEQ ID NO:10) primers using Pfu polymerase and the appropriate buffer with the following thermal profile: 95°C for 30 sec, 58°C for 30 sec and 72°C for 180 sec (30 cycles). The PCR product thus obtained was gel purified and cloned into pCRII vector to generate clone #1\_CR\_1-1895.7(-) (in the anti-clockwise orientation). Sequence analysis of several clones confirmed the identity of the cloned sequence.

Colon RNA from the first rhesus monkey was used to generate an additional PCR fragment by RT-PCR, essentially as described above. Oligonucleotide primers used for this purpose were as follows: 1558-1583 (SEQ ID NO:12) and 2798-2776 (SEQ ID NO:13) (Reaction 6, FIGURE 4). This fragment, located in the center portion of the HER2/neu gene, was used as a template for further amplification, without cloning.

Primers were then designed to PCR-amplify this region from bp 1621 to bp 2277 (FIGURE 4, Reactions 7, SEQ ID NOs: 14, 15) and from bp 2239 to 2798 (FIGURE 4, Reaction 8, SEQ ID NOs: 16 and 13). The resulting products were cloned into the pCRII vector. In order to inactivate the tyrosine kinase activity of the protein, primers were designed to mutate amino

acid position 579 from K to A (SEQ ID NOs:15 and 16). Sequence analysis of several clones confirmed the identity of the cloned sequences.

Colon RNA from the first rhesus monkey was used to generate an additional PCR fragment by RT-PCR, essentially as described above. Oligonucleotide primers used for this purpose were as follows: 2356-2378 (SEQ ID NO:17) and 4166-4145 (SEQ ID NO:18) (FIGURE 4, Reaction 9). The resulting product was cloned into the pCRII vector. Sequence analysis confirmed the identity of the cloned sequences.

DNA fragments were PCR amplified from the three above clones using the following primers: 1621-1644 (SEQ ID NO 14) and 2277-K753-2248 (SEQ ID NO 15) with template #1\_CR\_1621-2277.2; 2239-K756-2248 (SEQ ID NO 16) and 2798-2776 (SEQ ID NO 13) with template #1\_CR\_2239-2798.4; 2356-2378 (SEQ ID NO 17) and SalI\_3768-3746 (SEQ ID NO 19) with template #1\_CR\_2356-4169.2. The three products were assembled by PCR as described above. The resulting ligation product was amplified using the following primers: 1621-1644 (SEQ ID NO:14) and SalI\_3768-3746 '(SEQ ID NO:19) and cloned into pCRII vector in the clockwise orientation, generating clones #1-CR\_1621-3768.8 (hereinafter clone 10.8) and #1-CR\_1621-3768.12 (hereinafter clone 10.12) (FIGURE 4, Reactions 10). Sequencing revealed that clone 10.12 had a mutation around position 3686 in the 3' region. Simialry, clone 10.8 had a mutation around postion 2666. A wild type sequence was generated by replacinga 508 bp *Bst*EII-SalI fragment from clone 10.12 with the corresponding region from clone 10.8, which did not include mutations in this region. The resulting clone was named #1-CR\_1621-3768.128.

A *Pml*II-XbaI fragment from clone #1\_CR\_1621\_3768.128(+) was cloned into the *Pml*II-SpeI sites of clone #1\_CR\_1\_1895.7(-). The resulting plasmid, which contains the entire rhesus HER2/neu coding sequence, was named #1\_CR\_1-3768(-). Sequence analysis confirmed the identity of the sequence.

### EXAMPLE 3

#### Immunogens

For gene transduction and immunization studies, the rhHER2/neu coding region was excised from #1\_CR\_1-3768(-) by digestion with *Pme*I and *Sal*I and inserted into the *Eco*RV and *Sal*I sites of mammalian expression plasmid pV1J\_nsA (Montgomery et al., *DNA Cell Biol.* 12(9): 777-83 (1993)), generating pV1J-rh-HER2/neu.

For adenovirus vector construction, the rhHER2/neu-encoding sequence was excised from #1\_CR\_1-3768(-) by digestion with *Pme*I and *Sal*I and cloned into the corresponding site of the ppolyMRKAd5ΔE1 shuttle plasmid, generating pMRKAd5ΔE1-

rhHER2/neu. Shuttle vector pMRKAd5ΔE1 contains Ad5 sequences from b.p. 1 to b.p. 450 and from b.p. 3511 to b.p. 5798 with an expression cassette containing human cytomegalovirus (HCMV) promoter (without intron A) and bovine growth hormone polyadenylation signal. The plasmid was recombined with the adenoviral backbone vector pMRKAd5HVO , which contains all Ad5 sequences except those encompassing the E1 and E3 regions, using *E. coli* BJ5183 cells (Chartier et al., *J. Virol.* 70: 4805-10 (1996)).

For vector production, pMRKAd5-rhHER2/neu was linearized by digestion with *PacI* and transfected in PerC.6 cells using Lipofectamine (Life Technologies, Rockville, MD). 5-6 viral passages were performed to amplify viral titer and a large viral amplification was carried out with a final production of 1.3x10<sup>12</sup> physical particles (pp). No genome rearrangements were detectable in the viral genome purified from the amplified vector, as indicated by restriction fragment length polymorphism (RFLP) analysis. The expected DNA fragments were observed both in the viral genome and in the control pMRKAd5-HER2/neu plasmid, restricted in parallel.

#### EXAMPLE 4

##### Isolation of HER2/neu-encoding DNA from a Second Rhesus Monkey

A similar sequencing analysis of RT-PCR products was performed using colon RNA from a second rhesus monkey (see EXAMPLE 1). Data acquired by sequencing many different amplification products encompassing the whole gene identified a second rhesus HER2/neu sequence, disclosed herein as SEQ ID NO:40, (hereinafter “second rhesus HER2 nucleotide sequence” or “rhHER2#2,” see FIGURE 5), with the deduced amino acid sequence disclosed herein as SEQ ID NO:41 (hereinafter “second rhesus HER2 amino acid sequence,” see FIGURE 6).

As in EXAMPLE 1, amplification products were generated by RT-PCR of total colon RNA from the second rhesus monkey using primers spanning the HER2/neu gene (see FIGURE 3). The resulting amplification products were gel-purified and sequenced. Additionally, these products were cloned into either the BS or the CR vector. DNA sequencing analysis of the resulting clones confirmed the rhHER2/neu nucleotide sequences obtained by direct sequencing of amplification products.

Eight differences were detected between rhHER2#1 and rhHER2#2 (for details, see FIGURE 7). Five of these mutations introduce an amino acid change in the protein as compared to the first rhesus HER2 amino acid sequence (SEQ ID NO:2). Of note, three of these mutations do not produce amino acid changes in the rhHER2#2 protein as compared with the rhHER2#1 protein.

## EXAMPLE 5

### Immunization of Rhesus Macaques with rhHER2/neu

In order to assess the efficiency of immunization of Rhesus macaques (*Macaca mulatta*) with the rhesus homologues of the human tumor antigen HER2/neu, which is expressed in colorectal carcinomas, immunization studies were performed at the Biomedical Primate Research Centre (BPRC), Rijswijk (The Netherlands). The studies were designed to evaluate both B and T cell responses to immunization with the rhesus HER2/neu antigen.

In a first study, one group of monkeys (4 rhesus monkeys total; 2 males and 2 females) were immunized with a plasmid DNA vector or an adenovirus vector expressing the rhesus homologue of the human tumor antigen HER2/neu (pV1J-rhHER2). For priming, animals were vaccinated intramuscularly (i.m.) with plasmid DNA at weeks 0, 4, 8, 12, and 16, by injection of DNA followed by electrical stimulation. The DNA was injected as a 1 ml solution (split over 2 sites with 0.5 ml/site) containing 5 mg pV1J-rhHER2 plasmid DNA for animals weighing 2-5 kilos. Animals are injected under anesthesia (mixture of ketamine/xylazine).

For electrostimulation, 2 trains of 100 square bipolar pulses (1 sec each), were delivered every other second for a total treatment time of 3 sec. The pulse length was 2 msec/phase with a pulse frequency and amplitude of 100 Hz and 100 mA (constant current mode), respectively.

The same group of animals was boosted by i.m. injection of Adenovirus 5 (Ad5) expressing rhesus HER2/neu. A ΔE1-ΔE3, "first generation" Adenovirus (P2 level) was used. A total amount of 10 exp11 viral particles (vp) were injected at week 24 and 28.

A further boosting was carried out by i.m. injection of 10exp11 viral particles (vp) of Adenovirus 24 (Ad24) expressing rhesus HER2/neu at weeks 36 and 40. Ad24 was chosen because neutralizing antibodies induced by Ad5 injection do not interfere with Ad24 infection.

To measure the immune response to HER2/neu induced by the above immunization protocol, blood samples were collected every four weeks for a total duration of one year. The HER2-specific cell mediated immune response was measured by IFN $\gamma$  ELISPOT assay. The number of IFN- $\gamma$  -secreting anti-rhesus HER2 T cells was determined by ELISPOT on PBMC using pools of peptides. Three hundred and eleven peptides, each 15 amino acids long, overlapping by 11 residues and spanning the entire rhesus protein sequence, were combined into eleven pools indicated with alphabetical letters from A to K (from N- to C- terminus). The frequency of IFN- $\gamma$  producing PBMC was calculated as the average value of

spots derived from duplicates at two different cell concentrations. Values were expressed as the number of spot forming colonies (SFC)/ $10^6$  total PBMC, minus the background values determined in the absence of peptides (typically less than 10 SFC/ $10^6$  total spleen cells). Calculated results indicate that all four monkeys showed a detectable cell-mediated response, as measured by IFN- $\gamma$  ELISPOT.

Reactivity was confirmed and typed by IFN- $\gamma$ + intracellular staining (ICS), which measured the frequency of CD4 $^+$  or CD8 $^+$  T-cell secreting IFN- $\gamma$ . CD3 $^+$  lymphocytes were collected by simultaneously gating on CD3 $^+$  events and small lymphocytes. Values higher than 0.1 % were considered positive. A positive value of 0.19 (CD8 $^+$ ) was obtained for monkey RI504 for pool J. No detectable anti-rhHER2 antibodies titres ( $> 200$ ) were detected.

In summary, i.m. injection of plasmid DNA expressing rhesus HER2/neu was effective in breaking tolerance and inducing a detectable cell-mediated immune response against rhHER2/neu in rhesus monkeys

#### EXAMPLE 6

##### Immunization of Rhesus Macaques with Rhesus Homologs of Human Tumor-Associated Antigens

A second series of immunization studies were performed at the Biomedical Primate Research Centre (BPRC), Rijswijk (The Netherlands) in order to assess the efficiency of immunization of Rhesus macaques (*macaca mulatta*) with rhesus homologues of the human tumor antigens HER2/neu, Ep-CAM and CEA, which are all expressed in colorectal carcinomas. Protocols were designed to evaluate both B and T cell responses to these tumor antigens in combination.

In this study, a second group of 4 rhesus monkeys (2 males and 2 females) were immunized with a mixture of three plasmid DNA vectors expressing the rhesus homologues of human tumor antigens Ep-CAM (pV1J-rhHER2), CEA (pV1J-rhCEA), and HER2/neu (pV1J-rhEpCAM).

Animals were primed by i.m. injection of plasmid DNA at weeks 0, 4, 8, 12, and 16, followed by electrostimulation. The DNA injection consisted of a 1 ml solution (split over 2 sites with 0.5 ml/site) containing 6 mg plasmid DNA (2 mg for each of the three TAAs) for animals weighing 2-5 kilos. Animals were injected under anesthesia (mixture of ketamine/xylazine).

For electrostimulation, 2 trains of 100 square bipolar pulses (1 sec each), were delivered every other second for a total treatment time of 3 sec. The pulse length was 2

msec/phase with a pulse frequency and amplitude of 100 Hz and 100 mA (constant current mode), respectively.

The same group of animals was boosted by injection of a mixture of three Ad5-expressing rhesus HER2/neu (Ad5-rhHER2), rhesus CEA (Ad5-rhCEA) and rhesus EpCAM (Ad5-rhEpCAM). A total amount of  $3 \times 10^{11}$  viral particles (vp), were injected i.m. at weeks 23 and 27 ( $1 \times 10^{11}$  vp for each of the three viruses).

A further boosting was carried out by i.m. injection of a mixture of three Ad24-expressing rhesus HER2/neu (Ad24-rhHER2), rhesus CEA (Ad24-rhCEA) and rhesus EpCAM (Ad24-rhEpCAM). A total amount of  $3 \times 10^{11}$  viral particles (vp), were injected i.m. at weeks 36 and 40 ( $1 \times 10^{11}$  vp for each of the three viruses).

To measure the immune response to HER2/neu using the above immunization protocol, blood samples were collected every four weeks for a total duration of one year. The cell mediated immune response was measured by IFN- $\gamma$  ELISPOT and intracellular staining, whereas the humoral response was measured by ELISA.

Monkeys RI449 and RI519 showed a detectable HER2-specific cell-mediated response, as measured by IFN- $\gamma$  ELISPOT analysis. A similar analysis did not detect any response against rhCEA and rhEpCAM. No detectable anti-rhHER2 antibodies titres (> 200) were detected.

In a third study, 4 rhesus monkeys were immunized with a mixture of Ad5-rhHER2, Ad5-rhCEA and Ad5-rhEpCAM by i.m. injection of Ad5 derivatives at weeks 0, 2 and 4. A 1 ml solution (split over 2 sites with 0.5 ml/site) containing  $3 \times 10^{11}$  vp ( $10^{11}$  for each of the three Ad5 virus) was administered to animals weighing 2-5 kilos, under anesthesia (mixture of ketamine/xylazine).

The same group of animals was boosted at weeks 24, 26 and 28 by i.m. injection of a mixture of Ad24-rhHER2, Ad24-rhCEA and Ad24-rhEpCAM (a total amount of  $3 \times 10^{11}$  vp,  $10^{11}$  vp for each of the three viruses). The cell mediated response was measured by IFN $\gamma$  ELISPOT assay. For monkeys RI514 and RI496, reactivity was typed by IFN- $\gamma$  intracellular staining. Three out of four monkeys showed a detectable response. In addition, anti-rhHER2 antibody titres ranging from 200 to 500 were detected in the three monkeys where a cell-mediated response was measured.

This immunization protocol was also effective in breaking tolerance and inducing anti-rhCEA cell-mediated and humoral immune responses. Monkey RI514 showed a measurable cell mediated response by IFN- $\gamma$  ELISPOT analysis. Intracellular staining confirmed this response. The same monkey also showed anti-rhCEA antibodies titres ranging from 500 to 1000. By contrast, a similar analysis did not detect any response against rhEpCAM.

In summary, the immunization protocol discussed above was effective in inducing a specific immune response against rhHER2/neu and rhCEA in rhesus monkeys.

**WHAT IS CLAIMED IS:**

1. An isolated nucleic acid molecule comprising a sequence of nucleotides that encodes a rhesus monkey HER2/neu protein as set forth in SEQ ID NO:2 or SEQ ID NO:41.
2. The isolated nucleic acid molecule of claim 1 wherein the nucleic acid is DNA.
3. The isolated nucleic acid molecule of claim 1 wherein the sequence of nucleotides comprises the sequence of nucleotides set forth in SEQ ID NO:1, SEQ ID NO:40, SEQ ID NO:42, or SEQ ID NO:43.
4. A vector comprising the nucleic acid molecule of claim 1.
5. A host cell comprising the vector of claim 4.
6. A process for expressing a rhesus HER2/neu protein in a recombinant host cell, comprising:
  - (a) introducing a vector comprising the nucleic acid of claim 1 into a suitable host cell; and,
  - (b) culturing the host cell under conditions which allow expression of said rhesus HER2/neu protein.
7. An isolated and purified rhesus HER2/neu polypeptide comprising a sequence of amino acids as set forth in SEQ ID NO:2 or SEQ ID NO:41.
8. A method of preventing or treating cancer comprising administering to a mammal a vaccine vector comprising an isolated nucleic acid molecule, the isolated nucleic acid molecule comprising a sequence of nucleotides that encodes a rhesus monkey HER2/neu protein as set forth in SEQ ID NO:2 or SEQ ID NO:41.
9. A method according to claim 8 wherein the mammal is human.
10. A method according to claim 8 wherein the vector is an adenovirus vector or a plasmid vector.

11. A method according to claim 8 wherein the vector is a plasmid vaccine vector, which comprises a plasmid portion and an expressible cassette comprising

- (a) a polynucleotide encoding a rhesus monkey HER2/neu protein; and
- (b) a promoter operably linked to the polynucleotide.

12. An adenovirus vaccine vector comprising an adenoviral genome with a deletion in the E1 region, and an insert in the E1 region, wherein the insert comprises an expression cassette comprising:

- (a) a polynucleotide encoding a rhesus monkey HER2/neu protein; and
- (b) a promoter operably linked to the polynucleotide.

13. A vaccine plasmid comprising a plasmid portion and an expression cassette portion, the expression cassette portion comprising:

- (a) a polynucleotide encoding a rhesus monkey HER2/neu protein; and
- (b) a promoter operably linked to the polynucleotide.

14. A method of protecting a mammal from cancer comprising:

- (a) introducing into the mammal a first vector comprising:

(i) a polynucleotide encoding a rhesus monkey HER2/neu protein;

and

(ii) a promoter operably linked to the polynucleotide;

- (b) allowing a predetermined amount of time to pass; and

- (c) introducing into the mammal a second vector comprising:

(i) a polynucleotide encoding a rhesus monkey HER2/neu protein;

and

(ii) a promoter operably linked to the polynucleotide.

15. A method according to claim 14 wherein the first vector is a plasmid and the second vector is an adenovirus vector.

16. A method according to claim 14 wherein the first vector is an adenovirus vector and the second vector is a plasmid.

17. A method of treating a mammal suffering from an epithelial-derived carcinoma comprising:

- (a) introducing into the mammal a first vector comprising:
  - (i) a polynucleotide encoding a rhesus monkey HER2/neu protein;

and

- (ii) a promoter operably linked to the polynucleotide;

- (b) allowing a predetermined amount of time to pass; and

- (c) introducing into the mammal a second vector comprising:

- (i) a polynucleotide encoding a rhesus monkey HER2/neu protein;

and

- (ii) a promoter operably linked to the polynucleotide.

18. A method according to claim 17 wherein the first vector is a plasmid and the second vector is an adenovirus vector.

19. A method according to claim 17 wherein the first vector is an adenovirus vector and the second vector is a plasmid.

20. A method according to claim 17 wherein the first and second vectors are adenovirus vectors.

## Nucleotide Sequence of First Rhesus HER2/Neu

1 ATGGAGCTGG CGGCCTGGTA CCGCTGGGGG CTCCCTCTCG CCCTCTTGCC CCCCCGGAGCT  
 61 GCGGGCACCC AAGTGTGCAC CGGCACAGAC ATGAAGCTGC GGCTCCCTGC CAGTCCCGAG  
 121 ACCCACCTGG ACATGCTCCG CCACCTCTAC CAGGGCTGCC AGGTGGTGCA GGGTAACCTG  
 181 GAACTCACCT ACCTGCCAAC CAATGCCAGC CTCTCCTTCC TGCAAGGATAT CCAGGAGGTG  
 241 CAGGGCTACG TGCTCATCGC TCACAACCAA GTGAGGCAGG TCCCCTGCA GAGGCTGCGG  
 301 ATTGTGCGAG GCACCCAGCT CTTTGAGGAC AACTATGCC C TGGCCGTGCT AGACAATGGA  
 361 GACCTGCTGA ACAATACCAC CCCTGTCACA GGGGCCTCCC CAGGAGGCCT GCGGGAGCTG  
 421 CAGCTTCGAA GCCTCACAGA GATCTTGAAA GGAGGGGTCT TGATCCAGCG GAACCCCCAG  
 481 CTCTGCTACC AGGACACGAT TTTGTGGAAG GACATCTTCC ATAAGAACAA CCAGCTGGCT  
 541 CTCACACTGA TCGACACCAA CCGCTCTCGG GCCTGCCACC CCTGTTCTCC AGTGTGTAAG  
 601 GGCTCCCGCT GCTGGGGAGA GAGTTCTGAG GATTGTCAAGA GCCTGACGCG CACTGCTGT  
 661 GCCGGTGGCT GTGCCCGCTG CAAGGGGCCA CTGCCCACTG ACTGCTGCCA TGAGCAGTGT  
 721 GCTGCCGGCT GCACGGGCCA CAAGCACTCT GACTGCCTGG CCTGCCTCCA CTTCAACCAC  
 781 AGCGGCATCT GTGARCTGCA CTGCCAGCC CTGGTCACCT ACAACACAGA CACCTTGAG  
 841 TCCATGCCCA ACCCGAGGG CCGGTATACA TTCGGCGCCA GCTGTGTGAC TGCCTGTCCC  
 901 TACAACCTACC TTTCTACGGA CGTGGGATCC TGCAACCCTCG TCTGCCCTGC GCACAACCAA  
 961 GAGGTGACAG CGGAGGACGG AACACAGCGA TGTGAGAAGT GCAGCAAGCC CTGTGCCCGA  
 1021 GTGTGCTATG GTCTGGGCAT GGAGCACTTG CGAGAGGTGA GGGCGGTAC CAGTGCCAAT  
 1081 ATCCAGGAGT TTGCTGGCTG CAAGAAGATC TTTGGGAGCT TGGCATTCT GCCAGAGAGC  
 1141 TTTGATGGCG ACCCAGCTC CAACACCGCC CCGCTTCAGC CGGAGCAGCT CCGAGTGTGTT  
 1201 GAGACTCTGG AAGAGATCAC AGGTTACCTA TACATCTCAG CATGGCCAGA CAGCCTGCCT  
 1261 GACCTTAGCG TCCTCCAGAA CCTGCAAGTA ATCCGGGGAC GAATTCTGCA CAATGGCGCC  
 1321 TACTCACTGA CCCTGCAAGG GCTGGCATC AGCTGGCTGG GGCTGCGCTC GCTGAGGGAA  
 1381 CTGGGCAGTG GACTGGCCCT CATCCACCAT AACACCCGCC TCTGCTTTGT GCACACGGTG  
 1441 CCCTGGGACC AGCTCTTCCG GAACCCGCAC CAAGCCCTGC TCCACACTGC CAACCGGCCA  
 1501 GAGGACGAGT GTGTGGCGA GGGCCTGGCC TGCCACCAGC TGTGCGCCCG AGGGCACTGC  
 1561 TGGGGTCCAG GGCCCACCCA GTGTGTCAC TGCAAGCAGT TCCTCGGGG CCAGGAGTGC  
 1621 GTGGAGGAAT GCCGAGTACT GCAGGGGCTC CCCAGGGAGT ATGTGAATGC CAGACACTGT  
 1681 TTGCGGTGCC ACCCTGAGTG TCAGCCCCAG AATGGCTCAG TGACATGTT TGGACCGGAG  
 1741 GCTGACCACT GTGTGGCCTG TGCCCACTAT AAGGACCCCTC CCTTCTGCGT GGCCCGCTGC  
 1801 CCCAGCGGTG TGAAACCTGA CCTCTCCTAC ATGCCCATCT GGAAGTTTCC AGATGAGGAG  
 1861 GGCACGTGCC AGTCTTGCCTC CATCAACTGC ACCCACTCCT GTGTGGACCT GGATGACAAG  
 1921 GGCTGCCCG CCGAGCAGAG AGCCAGCCCT CTGACGTCCA TCATCTCTGC TGTGGTGGGC  
 1981 ATTCTGCTGG TCGTGGTCTT GGGGGTGGTC TTTGGAATCC TCATCAAGCG ACGGCAGCAG  
 2041 AAGATCCGGA AGTACACGAT GCGGAGGCTG CTGCAGGAAA CGGAGCTGGT GGAGCCACTG  
 2101 ACACCGAGTG GAGCGATGCC CAACCAGGCG CAGATGCGGA TCCTGAAAGA GACGGAGCTG  
 2161 AGGAAGGTGA AGGTGCTTGG ATCTGGAGCT TTTGGCACAG TCTACAAGGG CATCTGGATC  
 2221 CCTGATGGGG AGAATGTGAA AATTCCAGTG GCCATCAAAG TGTGAGGGAA AACACATCC

2/9

2281 CCCAAAGCCA ACAAAGAAAT CTTAGACGAA GCATATGTGA TGGCTGGTGT GGGCTCCCCA  
2341 TATGTCTCCC GCCTCCTGGG CATCTGCCTG ACATCCACGG TGCAAGCTGGT GACACAGCTT  
2401 ATGCCCTATG GCTGCCTCTT AGACCATGTC CGAGAAAACC GCGGACGCCT GGGCTCCAG  
2461 GACCTGCTGA ACTGGTGTAT GCAGATTGCC AAGGGGATGA GCTACCTGGA GGATGTGCGG  
2521 CTCGTACACA GGGACTTGGC TGCTCGGAAC GTGCTGGTCA AGAGTCCCAA CCATGTCAA  
2581 ATTACAGACT TTGGGCTGGC TCGGCTGCTG GACATTGACG AGACAGAGTA CCATGCAGAT  
2641 GGGGGCAAGG TGCCCATCAA GTGGATGGCG CTGGAGTCCA TTCTCCGACG GCGGTTCAC  
2701 CACCAGAGTG ATGTGTGGAG TTATGGTGTG ACTGTGTGGG AGCTGATGAC TTTTGGGGCC  
2761 AAACCTTACG ATGGGATCCC AGCCCGGGAG ATCCCTGACC TGCTGGAAAA GGGGGAGCGG  
2821 CTGCCCGAGC CCCCCATCTG CACCATTGAT GTCTACATGA TCATGGTCAA ATGTTGGATG  
2881 ATTGACTCTG AATGTCGGCC GAGATTCCGG GAGTTGGTGT CGGAATTCTC CCGCATGGCC  
2941 AGGGACCCCC AGCGCTTTGT GGTCACTCAG AATGAGGACT TGGGCCAGC CAGTCCCTTG  
3001 GACAGCACCT TCTACCGCTC ACTGCTGGAG GACGATGACA TGGGGGACCT GGTGGATGCT  
3061 GAGGAGTATC TGGTACCCCA GCAGGGCTTC TTCTGTCCAG ACCCTGCCCG GGGCACTGGG  
3121 GGCATGGTCC ACCACAGGCA CCGCAGCTCA TCTACCAGGA GTGGCGGTGG GGACCTGACG  
3181 CTAGGGCTGG AGCCCTCTGA AGAGGAGGCC CCCAGGTCTC CACGGGCACC CTCCGAAGGG  
3241 ACTGGCTCTG ATGTATTGAG TGGTACCTA GGAATGGGGG CAGCCAAGGG GCTGCAAAGC  
3301 CTCCCCGCAC ATGACCCCCAG CCCTCTACAG CGGTACAGTG AGGACCCCAC GGTACCCCTG  
3361 CCTTCTGAGA CTGACGGCTA CGTTGCCCG CTGACCTGCA GTCCCCAGCC CGAATATGTG  
3421 AACCAAGCCAG ATGTTCGGCC ACAGCCCCCT TCGCCCCAAG AGGGCCCTCT GTCTCCTGCC  
3481 CGACCTACTG GTGCCACTCT GGAAAGGCC AAGACTCTCT CCCCAGGGAA GAATGGGGTT  
3541 GTCAAAGACG TTTTGCCCTT TGGGGGTGCT GTGGAGAACCC CCGAGTACTT GGCACCCCCGG  
3601 GGAGGAGCTG CCCCTCAGCC CCACCTTCCT CCTGCCTTCA GCCCAGCCTT CGACAAACCTC  
3661 TATTACTGGG ACCAGGACCC ATCAGAGCGG GGGGCTCCAC CTAGCACCTT CAAAGGGACA  
3721 CCTACGGCAG AGAACCCAGA GTACCTGGGT CTGGACGTGC CAGTGTGA (SEQ ID N:1)

FIG. 1B

Predicted Amino Acid Sequence of First Rhesus  
Her2/Neu Protein (SEQ ID NO:2)

1 MELAAWYRWG LLLALLPPGA AGTQVCTGTD MKLRLPASPE THLDMLRHLY QGCQVVQGNL  
61 ELTYLPTNAS LSFLQDIQEV QGYVLIAHNQ VRQVPLQRRL IVRGSQLFED NYALAVLDNG  
121 DLLNNNTTPVT GASPGGLREL QLRLSLTEILK GGVLIQRNQPQ LCYQDTILWK DIFHKNNQLA  
181 LTLIDTNRSR ACHPCSPVCK GSRCWGESS E DCQSLTRTVC AGGCARCKGP LPTDCCHEQC  
241 AAGCTGPKHS DCLACLHFNH SGICELHCPA LVTYNTDTFE SMPNPEGRYT FGASCVTACP  
301 YNYLSTDVGS CTLVCPLHNQ EVTAEDGTQR CEKCSKPCAR VCYGLGMEHL REVRAVTSAN  
361 IQEFAGCKKI FGSLAFLPES FDGDPAASNTA PLQPEQLRVF ETLEEITGYL YISAWPDSLP  
421 DLSVLQNLQV IRGRILHNGA YSLTLQGLGI SWLGLRSLRE LGSGLALIHH NTRLCFVHTV  
481 PWDQLFRNPH QALLHTANRP EDECVGEGLA CHQLCARGHC WGPGBTQCVN CSQFLRGQEC  
541 VEECRVLQGL PREVNARHC LPCHPECQPQ NGSVTCFGPE ADQCVACAHY KDPPFCVARC  
601 PSGVKPDLSY MPIWKFPDEE GTCQSCPINC THSCVDLDDK GCPAEQRASP LTSIISAVVG  
661 ILLVVVLGVV FGILIKRRQQ KIRKYTMRRRL LQETELVEPL TPSGAMPNQA QMRILKETEL  
721 RKVKVLGSGA FGTVYKGWI PDGENVKIPV AIKVLRENTS PKANKEILDE AYVMAGVGSP  
781 YVSRLLGICL TSTVQLVTQL MPYGCLLDHV RENRGRLGSQ DLLNWCMQIA KGMSYLEDVR  
841 LVHRDLAARN VLVKSPNHWK ITDFGLARLL DIDETEYHAD GGKVPIKWMA LESILRRRT  
901 HQSDVWSYGV TVWELMTFGA KPYDGIPARE IPDLLEKGER LPQPPPICTID VYMIMVKCWM  
961 IDSECRPRFR ELVSEFSRMA RDPQRFFVIQ NEDLGPASPL DSTFYRSLL DDDMGDLVDA  
1021 EEYLVPQQGF FCPDPAPGTG GMVHHHRRSS STRSGGGDLT LGLEPSEEEA PRSPRAPSEG  
1081 TGSDVFDGDL GMGAAKGLQS LPAHDPSPLQ RYSEDPTVPL PSETDGYVAP LTCSPQPEYV  
1141 NQPDVRPQPP SPQEGPLSPA RPTGATLERP KTLSPGKNGV VKDVFAFGGA VENPEYLAPR  
1201 GGAAPQPHLP PAFSPAFDNL YYWDQDPSER GAPPSTFKGT PTAENPEYLG LDVPV\*

**FIG.2**

4/9

## Oligonucleotide Primers Spanning Rhesus Her2/neu Gene

Forward	Sequence	Reverse	Sequence
(-30)-(-10)	AGCAATGGGCGGCGGAA (SEQ ID NO:3)	96-79	CTTCATGCTGTCGCTGT (SEQ ID NO:20)
(-22)-(-1)	CCCGCAGGCGAGCTGAC (SEQ ID NO:21)	431-409	CTTCAGAATGCGAGCTCGCGAG (SEQ ID NO:22)
1-25	ATGGACCTGGGGCGCTTCCCT (SEQ ID NO:23)	812-787	AGGGCTGGCAGTCAGCTACAGAT (SEQ ID NO:4)
79-96	ACCCACACACAATGAAAC (SEQ ID NO:24)	1115-1096	CCAAAGAACCTTCCTGCACCC (SEQ ID NO:6)
409-431	CTGGGGAGCTGGCGCTTCCAG (SEQ ID NO:5)	1370-1352	CACGCCACCCCAACCC (SEQ ID NO:8)
787-812	ATCTCTGCTCCACTCCACCGCTT (SEQ ID NO:7)	1583-1588	CACCTCTGGCTGGCGCCCGCA (SEQ ID NO:25)
1096-1115	GGCTCGAAGAGATCTTTC (SEQ ID NO:9)	1895-1876	TCTCTGCACTTGATGGCGAA (SEQ ID NO:10)
1352-1370	CTCTGGCTGGCTGCGCTC (SEQ ID NO:27)	2163-2161	GATCCAGAACCTTCACCTCTCT (SEQ ID NO:26)
1558-1583	TGCTGGGGTCAAGGGCCACCGTC (SEQ ID NO:12)	2222-2200	CGGAATCCAGATGCGCTTGTAGAC (SEQ ID NO:28)
1876-1895	TGCCCCATCAACTGACCCA (SEQ ID NO:29)	2277-2253A-2239	TCTGTCTTCCCTCAACCGCATGGCCACTGGAAATT (SEQ ID NO:15)
2161-2183	AGGAATCTGAGGGCTGGATC (SEQ ID NO:31)	2518-2336	CTGGATAGTCAGGAGATGGCCAG (SEQ ID NO:30)
2200-2222	GTCCTACGGCATCTGGAATCCC (SEQ ID NO:33)	2768-2743	TATGGTTGGCTCAAAAGTCATAG (SEQ ID NO:32)
2239-K753A 2277	AAAATTCAGTGGCATGGCGCTTGTAGGGAAACACA (SEQ ID NO:16)	2798-2776	TCTGGAAATCTCGCTGGCTCTGGAT (SEQ ID NO:13)
2356-2378	CCTGGCATCTCCATCACCC (SEQ ID NO:17)	3410-3388	GGCTTCGGCTCTGGCTTCGGC (SEQ ID NO:34)
2743-2768	CCTGATGACTTCTGGCCAAACCTTA (SEQ ID NO:35)	SaiI_3768-3746	GGCTCTGGACTTCTACAGGCGCTTCAGCA (SEQ ID NO:19)
2776-2798	ATCCCAACCCGGAGATCCCTGA (SEQ ID NO:37)	3791-3770	TTCCTGGGGACTTCGGCTTCCTGC (SEQ ID NO:36)
JJ88-3410 2	CCCGCAGCTGGGGCGCC (SEQ ID NO:39)	3885-3869	TGGGAGGTTCCCTGGAA (SEQ ID NO:38)
1621-1644	GTGAGGAAATGGCGAGTACTGCG (SEQ ID NO:14)	4166-4145	GGTTTCAAGGACAGCTCTCGAA (SEQ ID NO:18)
PmeI_SwaI_RBS_1-16	CCAGTTAAACATTAAATGGCCGCCACCATGGCCCTGC GCCCT (SEQ ID NO:11)		

FIG. 3

5/9

RT-PCR Primers and Clones Used to Construct Full-Length rhHER2/neu Clone.

Rxn.#	Forward Oligonucleotide Primer	Reverse Oligonucleotide Primer	Clone
1	AGCCATGGGGGAGCCCA (SEQ ID NO:3)	AGGGCTGGGCAGTGCAGTCACAGAT (SEQ ID NO:4)	#1_BS_(-30)-812.A1
2	CTGGGGAGCTGCAGCTCGAAG (SEQ ID NO:5)	CCAAAGATCTCTTGAGCC (SEQ ID NO:6)	#1_CR_409_1115.2
3	ATCTGTGAGCTGCCACTGCCCT (SEQ ID NO:7)	GAGCCGAGCCCCAGCCAGC (SEQ ID NO:8)	#1_CR_787_1370.10
4	GGCTGCAAGAACATCTTGG (SEQ ID NO:9)	TGGGTGGCAGTTGATGGGCA (SEQ ID NO:10)	#1_BS_1096_1895.11
5	CCAGTTAAACATTAAATGCCGCCCACCATGGAGCTGG CGGCT (SEQ ID NO:11)	TGGGTGGCAGTTGATGGGCA (SEQ ID NO:10)	#1_CR_1-1895.7(-)
6	TGCTGGGTCCAGGGGCCACCCAGTG (SEQ ID NO:12)	TCAGGGATCTCCGGCTGGGAT (SEQ ID NO:13)	Not Cloned (1558-2798)
7	GTGAGGAATGCCGAGTACTGCAG (SEQ ID NO:14)	TGTGTTTCCCTCAACACGGCGATGGCCACTGGAAATTTC (SEQ ID NO:15)	#1_CR_1621-2277.2
8	AAAATTCCAGTGGCCATGCCGCTGTTGGGGAAACAC A (SEQ ID NO:16)	TCAGGGATCTCCGGCTGGGAT (SEQ ID NO:13)	#1_CR_2239-2798.4
9	CTGGCCATCTGCCATGCCAC (SEQ ID NO:17)	GGTTTCAGGGCACACTCTCTGAA (SEQ ID NO:18)	#1_CR_2356-4166.2
10	GTGAGGAATGCCGAGTACTGCAG (SEQ ID NO:14)	GCCGTCGACTTTACATGGACAGTCCAGACCCA (SEQ ID NO:19)	#1_CR_1621-3768.8(+)
10	GTGAGGAATGCCGAGTACTGCAG (SEQ ID NO:14)	GCCGTCGACTTTACATGGACAGTCCAGACCCA (SEQ ID NO:19)	#1_CR_1621-3768.12(+)

FIG. 4

## Nucleotide Sequence of Second Rhesus HER2/Neu

1 ATGGAGCTGG CGGCCTGGTA CCGCTGGGGG CTCCCTCTCG CCCTCTTGCC CCCC GGAGCT  
 61 GCGGGCACCC AAGTGTGCAC CGGCACAGAC ATGAAGCTGC GGCTCCCTGC CAGTCCCGAG  
 121 ACCCACCTGG ACATGCTCCG CCACCTCTAC CAGGGCTGCC AGGTGGTGCA GGGTAACCTG  
 181 GAACTCACCT ACCTGCCAAC CAATGCCAGC CTCTCCTTCC TGCAAGGATAT CCAGGAGGTG  
 241 CAGGGCTACG TGCTCATCGC TCACAACCAA GTGAGGCAGG TCCC ACTGCA GAGGCTGCCG  
 301 ATTGTGCGAG GCACCCAGCT CTTTGAGGAC AACTATGCCG TGGCCGTGCT AGACAATGGA  
 361 GACCCGCCTGA ACAATACCAC CCCTGTCA CA GGGGCCCTCCC CAGGAGGCCT GCGGGAGCTG  
 421 CAGCTTCGAA GCCTCACAGA GATCTTGAAA GGAGGGGTCT TGATCCAGCG GAACCCCCAG  
 481 CTCTGCTACC AGGACACGAT TTTGTGGAAG GACATCTTCC ATAAGAACAA CCAGCTGGCT  
 541 CTCACACTGA TCGACACCAA CCGCTCTCGG GCCTGCCACC CCTGTTCTCC AGTGTGTAAG  
 601 GGCTCCCGCT GCTGGGGAGA GAGTTCTGAG GATTGTCA GA GCCTGACGCG CACTGTCTGT  
 661 GCCGGTGGCT GTGCCGCTG CAAGGGGCCA CTGCCCACTG ACTGCTGCCA TGAGCAGTGT  
 721 GCTGCCGGCT GCACGGGCC CAAGCACTCT GACTGCCCTGG CCTGCCTCCA CTTCAACCAC  
 781 AGCGGCATCT GTGARCTGCA CTGCCAGCC CTGGTCACCT ACAACACAGA CACCTTGAG  
 841 TCCATGCCCA ACCCGAGGG CCGGTATAACA TTCCGGGCCA GCTGTGTGAC TGCCGTCCC  
 901 TACAAC TACC TTTCTACGGA CGTGGGATCC TGCAACCTCG TCTGCCCTGC GCACAACCAA  
 961 GAGGTGACAG CGGAGGACGG AACACAGCGA TGTGAGAAGT GCAGCAAGCC CTGTGCCGA  
 1021 GTGTGCTATG GTCTGGGCAT GGAGCACTTG CGAGAGGTGA GGGCGGTAC CAGTGCCAAT  
 1081 ATCCAGGAGT TTGCTGGCTG CAAGAAGATC TTTGGGAGY TGGCATTCT GCCAGAGAGC  
 1141 TTTGATGGCG ACCCAGCCTC CAACACCGCC CCGCTTCAGC CGGAGCAGCT CCGAGTGT  
 1201 GAGACTCTGG AAGAGATCAC AGGTTACCTA TACATCTCAG CATGGCCAGA CAGCCTGCCT  
 1261 GACCTTAGCG TCCTCCAGAA CCTGCAAGTA ATCCGGGAC GAATTCTGCA CAATGGCGCC  
 1321 TACTCACTGA CCCTGCAAGG GCTGGCCTC AGCTGGCTGG GGCTGCGCTC GCTGAGGGAA  
 1381 CTGGGCAGTG GACTGGCCCT CATCCACCAT AACACCCGCC TCTGCTTTGT GCACACGGTG  
 1441 CCCTGGGACC AGCTCTTCCG GAACCCGCAC CAAGCCCTGC TCCACACTGC CAACCGCCA  
 1501 GAGGACGAGT GTGTGGCGA GGGCCTGGCC TGCCACCAGC TGTGCGCCCR AGGGCACTGC  
 1561 TGGGGTCCAG GGCCCACCCA GTGTGTCAC TGCAAGCAGT TCCTCGGGG CCAGGAGTGC  
 1621 GTGGAGGAAT GCCGAGTACT GCAGGGGCTC CCCAGGGAGT ATGTGAATGC CAGACACTGT  
 1681 TTGCCGTGCC ACCCTGAGTG TCAGCCCCAG AATGGCTCAG TGACATGTT TGGACCGGAG  
 1741 GCTGACCACT GTGTGGCCTG TGCCCACTAT AAGGACCCCTC CCTTCTGCGT GGCCCGCTGC  
 1801 CCCAGCGGTG TGAAACCTGA CCTCTCCTAC ATGCCCATCT GGAAGTTTCC AGATGAGGAG  
 1861 GGCACGTGCC AGCCTGCC CATCAACTGC ACCCACTCCT GTGTGGACCT GGATGACAAG  
 1921 GGCTGCCCG CCGAGCAGAR AGCCAGCCCT CTGACGTCCA TCATCTCTGC TGTGGTGGC  
 1981 ATTCTGCTGG TCGTGGCTT GGGGGTGGC TTTGGAATCC TCATCAAGCG ACGGCAGCAG  
 2041 AAGATCCGA AGTACACGAT GCGGAGGCTG CTGCAGGAAA CGGAGCTGGT GGAGCCACTG  
 2101 ACACCGAGTG GAGCGATGCC CAACCAGGCG CAGATGCCGA TCCTGAAAGA GACGGAGCTG  
 2161 AGGAAGGTGA AGGTGCTTGG ATCTGGAGCT TTTGGCACAG TCTACAAGGG CATCTGGATC  
 2221 CCTGATGGGG AGAATGTGAA AATTCCAGTG GCCATCAAAG TGTTGAGGG AAACACATCC

7/9

2281 CCCAAAGCCA ACAAAAGAAAT CTTAGACGAA GCATATGTGA TGGCTGGTGT GGGCTCCCCA  
2341 TATGTCTCCC GCCTCCTGGG CATCTGCCTG ACATCCACGG TGCA~~G~~C~~T~~GGT GACACAGCTT  
2401 ATGCCCTATG GCTGCCTCTT AGACC~~A~~TGTC CGAGAAAACC GCGGACGCCT GGGCTCCCAG  
2461 GACCTGCTGA ACTGGTGTAT GCAGATTGCC AAGGGGATGA GCTACCTGGA GGATGTGCGG  
2522 CTCGTACACA GGGACTTG~~G~~C TGCTCGGAAC GTGCTGGTCA AGAGTCCCAA CCATGTCAAA  
2581 ATTACAGACT TTGGGCTGGC TCGGCTGCTG GACATTGACG AGACAGAGTA CCATGCAGAT  
2641 GGGGGCAAGG TGCCC~~A~~TCAA GTGGATGGCG CTGGAGTCCA TTCTCCGACG GC~~G~~GGTT~~C~~ACC  
2701 CACCAGAGTG ATGTGTGGAG TTATGGTGTG ACTGTGTGGG AGCTGATGAC TTTTGGGGCC  
2761 AAACCTTACG ATGGGATCCC AGCCC~~G~~GGAG ATCCCTGACC TGCTGGAAAA GGGGGAGCGG  
2821 CTGCCCCAGC CCC~~C~~CATCTG CACCATTGAT GTCTACATGA TCATGGTCAA ATGTTGGATG  
2881 ATTGACTCTG AATGTCGGCC GAGATTCCGG GAGTTGGTGT CGGAATTCTC CCGCATGGCC  
2941 AGGGACCCCC AGCGCTTTGT GGTCATCCAG AATGAGGACT TGGGCCAGC CAGTCCCTTG  
3001 GACAGCACCT TCTACCGCTC ACTGCTGGAG GACGATGACA TGGGGGACCT GGTGGATGCT  
3061 GAGGAGTATC TGGTACCCCCA GCAGGGCTTC TTCTGTCCAG ACCCTGCC~~C~~ GGGCACTGGG  
3121 GGCATGGTCC ACCACAGGCA CCGCAGCTCA TCTACCAGGA GTGGCGGTGG GGACCTGACG  
3181 CTAGGGCTGG AGCCCTCTGA AGAGGAGGCC CCCAGGTCTC CACRGGCACC CTCCGAAGGG  
3241 ACTGGCTCTG ATGTATTG~~A~~ TGGT~~G~~ACCTA GGAATGGGGG CAGCCAAGGG GCTGCAAAGC  
3301 CTCCCCG~~C~~AC ATGACCCCCAG CCCTCTACAG CGGTACAGTG AGGACCCCCAC GGTACCCCTG  
3361 CCTTCTGAGA CTGACGGCTA CGTTGCC~~CC~~ CTGACCTGCA GYCCCCAGCC CGAATATGTG  
3421 AACCA~~G~~CCAG ATGTT~~C~~GGCC ACAGCCCCCT TCGCCCCAAG AGGGCCCTCT GTCTCCTGCC  
3481 CGACCTACTG GTGCCACTCT GGAAAGGCC AAGACTCTCT CCCCAGGGAA GAATGGGGTT  
3541 GTCAAAGACG TTTTTGCCTT TGGGGGTGCT GTGGAGAAC~~C~~ CCGAGTACTT GGCACCCCCGG  
3601 GGAGGGAGCTG CCC~~C~~TCAGCC CCACCTTC~~C~~ CCTGCCTTCA GCCCAGCCTT CGACAACCTC  
3661 TATTACTGGG ACCAGGACCC ATCAGAGCGG GGGGCTCCAC CTAGCACCTT CAAAGGGACA  
3721 CCTACGGCAG AGAACCCAGA GTACCTGGGT CTGGACGTGC CAGTGTGA (SEQ ID NO:40)

FIG.5B

## Predicted Amino Acid Sequence of Second Rhesus Her2/Neu Protein

1 MELAAWYRWG LLLALLPPGA AGTQVCTGTD MKLRLPASPE THLDMLRHLY QGCQVVQGNL  
61 ELYLPTNAS LSFLQDIQEY QGYVLIAHNQ VRQVPLQRLR IVRGSQLFED NYALAVLDNG  
121 DPLNNTTPTV GASPGGLREL QLRSLTEILK GGVLIQRNPQ LCYQDTILWK DIFHKNNQLA  
181 LTLIDTNRSR ACHPCSPVCK GSRCWGESS DCQSLTRVC AGGCARCKGP LPTDCCHEQC  
241 AAGCTGPKHS DCLACLFHNH SGICELHCPA LVTYNTDTFE SMPNPEGRYT FGASCVTACP  
301 YNYLSTDVGS CTLVCPLHNQ EVTAEDGTQR CEKCSKPCAR VCYGLGMEL REVRAVTSAN  
361 IQEFAGCKKI FGSLAFLPES FDGDPASNTA PLQPEQLRVF ETLEEITGYL YISAWPDSLP  
421 DLSVLQNLQV IRGRILHNGA YSLTLQGLGI SWLGLRSLRE LGSGLALIHH NTRLCFVHTV  
481 PWDQLFRNPH QALLHTANRP EDECVGEGLA CHQLCA~~X~~GHC WGPGBTQCVN CSQFLRGQEC  
541 VEECRVLQGL PREYVNARHC LPCHPECQPQ NGSVTCFGPE ADQCVACAHY KDPPFCVARC  
601 PSGVKPDLSY MPIWKFPDEE GTCQPCPINC THSCVDLDDK GCPAEQ~~X~~ASP LTSIISAVVG  
661 ILLVVVLGVV FGILIKRRQQ KIRKYTMRRRL LQETELVEPL TPSGAMPNQA QMRILKETEL  
721 RKVKVLGSGA FGTVYKGWI PDGENVKIPV AIKVLRENTS PKANKEILDE AYVMAGVGSP  
781 YVSRLLGICL TSTVQLVTQL MPYGCLLDHV RENRGRLGSQ DLLNWCMQIA KGMSYLEDVR  
841 LVHRDLAARN VLVKSPNHVK ITDFGLARLL DIDETEYHAD GGKVPIKWMA LESILRRRFT  
901 HQSDVWSYGV TVWELMTFGA KPYDGIAPARE IPDLLEKGER LPQPPICTID VYMIMVKCWM  
961 IDSECRPRFR ELVSEFSRMA RDPQRFFVIQ NEDLGPASPL DSTFYRSLLE DDDMGDLVDA  
1021 EYLVPQQGF FCPDPAPGTG GMVHHHRRSS STRSGGGDLT LGLEPSEEEA PRSP~~X~~APSEG  
1081 TGSDVFDGDL GMGAAKGLQS LPAHDPSPLQ RYSEDPTVPL PSETDGYVAP LTCSPQPEYV  
1141 NQPDVVRPQPP SPQEGPLSPA RPTGATLERP KTLSPGKNGV VKDVFAFGGA VENPEYLAPR  
1201 GGAAPQPHLP PAFSPAfdnl YYWDQDPSER GAPPSTFKGT PTAENPEYLG LDVPV\*  
(SEQ ID NO:41)

**FIG.6**

9/9

## MUTATIONS IN RHESUS HER2/neu NUCLEOTIDE SEQUENCE

POSITION	RhHER2#1	RhHER2#2
365	2 CLONES C T G S L	2 CLONES C C G S P
795	3 CLONES G A G E E 2 CLONES G A A E E	1 CLONE G A G E E 2 CLONES G A A E E
1119	2 CLONES A G C S S	3 CLONES A G T S S 2 CLONES A G C S S
1550	3 CLONES C G A R R	2 CLONES C A A Q Q 3 CLONES C G A R R
1873	6 CLONES T C T S S	11 CLONES C C T P P
1940	2 CLONES A G A R R	3 CLONES A A A K K 3 CLONES A G A R R
3224	4 CLONES C G G R R	5 CLONES C G G R R 3 CLONES C A G Q Q
3402	2 CLONES A G T S S	2 CLONES A G C S S 6 CLONES A G T S S

FIG.7

## SEQUENCE LISTING

<110> Merck & Co., Inc.  
Monaci, Paolo  
Nuzzo, Maurizio  
La Monica, Nicola  
Ciliberto, Gennaro  
Lahm, Armin

<120> RHESUS HER2/NEU, NUCLEOTIDES ENCODING  
SAME AND USES THEREOF

<130> ITR0043-PCT

<150> 60/437,846  
<151> 2003-01-03

<160> 43

<170> FastSEQ for Windows Version 4.0

<210> 1  
<211> 3768  
<212> DNA  
<213> Rhesus Monkey

<220>  
<221> misc\_feature  
<222> (1)...(3768)  
<223> R = A or G

<400> 1  
atggagctgg cggcctggta ccgctggggg ctcctcctcg ccctcttgc cccggagct 60  
gccccaccc aagtgtgcac cggcacagac atgaagctgc ggctccctgc cagtccccag 120  
accacacctgg acatgtccg ccacctctac cagggtgtgcc aggtggtgca gggtaacctg 180  
gaactcacct acctggccac caatgccgc ctctccctcc tgcaggatcat ccaggaggtg 240  
cagggtacg tgctcatcgc tcacaaccaa gtgagggcagg tcccactgca gaggctgcgg 300  
attgtgcag gcaccaggct ctttggggac aactatgtccc tggccgtgtc agacaatgg 360  
gacctgtca acaataccac ccctgtcaca ggggcctccc caggaggct gcgggagctg 420  
cagcttcgaa gcctcacaaga gatcttggaaa ggaggggctt tgatccagcg gaaccccccag 480  
ctctgttacc aggacacgt tttgtggaaag gacatcttcc ataagaacaa ccagctggct 540  
ctcacactga tcgacaccaa ccgtctctcg gcctgtccacc cctgttctcc agtgtgtaa 600  
ggctcccgct gctggggaga gagttctgag gattgtcaga gcctgacgcg cactgtctgt 660  
gcoggtggct gtgcccgtc caagggggcca ctgcccactg actgctgca tgagcagtgt 720  
gctgcccggct gcacggggcc caagcactt gactgtctgg cctgccttcca ttcaaccac 780  
agccggcatct gtgarctgca ctgcccagcc ctggtcaccc acaacacaga cacctttgag 840  
tccatgcccc accccgggg ccggtataaca ttccggccca gctgtgtac tgcctgtccc 900  
tacaactacc tttctacgga cgtgggatcc tgcaccctcg tctgccccct gcacaaccaa 960  
gaggtgacag cggaggacgg aacacagcga tgtgagaagt gcagcaagcc ctgtggccga 1020  
gtgtgtatg gtctggcat ggagcacttgc cgagaggtga gggcggtcac cagtgc当地 1080  
atccaggagt ttgctggctg caagaagatc tttggggatct tggcatttct gccagagagc 1140  
tttgatggcg acccagcctc caacacccgccc cccgttccgc cggagcagct ccgagtgttt 1200  
gagactctgg aagagatcac aggttaccta tacatctcag catggccaga cagccctgcct 1260  
gaccttagcg tcctccagaa cctgcaagta atccggggac gaattctgca caatggccgc 1320  
tactcaactga ccctgcaagg gctgggcattc agctggctgg ggctgcgtc gctgagggaa 1380  
ctgggcagggt gactggccct catccacccat aacacccggcc tctgttctgt gcacacgggtg 1440  
ccctgggaccc agctttccg gaacccggcac caagccctgc tccacactgc caacccggcca 1500  
gaggacgagt gtgtgggcga gggcctggcc tgccaccagg tggcgcccg agggcactgc 1560  
tggggtccag gggccaccca gtgtgtcaac tgcagccgt tccttcgggg ccaggagtgc 1620  
gtggaggaaat gccgagactt gcaggggctc cccaggaggat atgtgaatgc cagacactgt 1680  
ttccggcgc accctgagtg tcagccccag aatggctcag tgacatgtt tggaccggag 1740  
gctgaccagggt gtgtggcctg tgcccaactat aaggaccctc cttctgcgt ggcccgctgc 1800  
cccagcggtg tgaaacctga cctctctac atgcccattt ggaagttcc agatgaggag 1860

ggcacgtgcc agtcttgccc catcaactgc acccactcct gtgtggacct ggatgacaag 1920  
 ggctgccccg ccgagcagag agccagccct ctgacgtcca tcatctctgc tgggtggc 1980  
 attctgtgg tcgtggctt ggggtggc tttggaatcc tcatcaagcg acggcagcag 2040  
 aagatccgga agtacacgat gcgaggctg ctgcaggaaa cggagctggt ggagccactg 2100  
 acaccgagtg gagcgatgcc caaccagggc cagatgcggc tcctgaaaga gacggagctg 2160  
 aggaaggtga aggtgcttgg atctggagct tttggcacag tctacaaggg catctggatc 2220  
 cctgatgggg agaatgtgaa aattccagtg gccatcaaag tggaggaa aaacacatcc 2280  
 cccaaagcca acaaagaaat cttagacgaa gcataatgtga tatgtctccc gcctcctggg catctgcctg acatccacgg 2340  
 atgcctatg gtcgcctctt agaccatgtc cgagaaaacc tgca gacacagctt 2400  
 gacctgctga actggtgtat gcagattgcc aaggggatga gcccacgcct gggctccag 2460  
 ctcgtacaca gggacttggc tgctcggAAC gtgtggtca attacagact ttgggctggc tcggctgtc gacattgacg 2520  
 gggggcaagg tgcccatcaa gtggatggcg ctggagtcca caccagagtg atgtgtggag ttatgggtgt actgtgtggg 2580  
 aaaccttacg atgggatccc agccccggag atccctgacc ctgcccccagc ccccatctg caccattgtat gtctacatga 2640  
 attgactctg aatgtcggcc gagattcccg gagttgggtgt agggacccccc agcgctttgt ggtcatccag aatgaggact 2700  
 gacagcacct tctacgcctc actgtggag gacgtacaca gaggagtatc tggtaaaaaa gggggagcgg 2760  
 gggcatggtcc accacaggca cgcgcgtctca tctaccaggaa ctggggacccat ggtggatgtc 2820  
 ctagggctgg agccctctga agaggaggcc cccaggtctc actggctctg atgtatttga tggtgaccta ggaatggggg 2880  
 ctccccgcac atgacccac ccctctacag cggtaacatgt cttctgccccctt cggcatggcc 2940  
 cttctgaga ctgacggcta cgttgcctt ctgacctgtca 3000  
 aaccagccag atgttcggcc acagccccct tcgccttca 3060  
 cgacctactg gtgcacactt ggaaaggccc aagactctct 3120  
 gtcaaagacg ttttgcctt tgggggtgt gtggagaacc 3180  
 ggaggagctg cccctcagcc ccaccttctt cctgccttca 3240  
 tattactggg accaggaccc atcagagccg gggctccac 3280  
 cctacggca agaaccaggaa gtagctgggt ctggacgtgc 3300  
 cagccaaagggg gctgcaaagg 3360  
 aggacccac ggtacccctg 3420  
 gtccccagcc cgaatatgtg 3480  
 agggccctct gtctcctgccc 3540  
 ccccaaggaa gaatgggtt 3600  
 ccgagtaactt ggcaccccg 3660  
 gcccagcct cgacaacctc 3720  
 ttagcacctt caaaggacca 3768  
 cagtgta

<210> 2  
 <211> 1255  
 <212> PRT  
 <213> Rhesus Monkey

<400> 2  
 Met Glu Leu Ala Ala Trp Tyr Arg Trp Gly Leu Leu Leu Ala Leu Leu  
 1 5 10 15  
 Pro Pro Gly Ala Ala Gly Thr Gln Val Cys Thr Gly Thr Asp Met Lys  
 20 25 30  
 Leu Arg Leu Pro Ala Ser Pro Glu Thr His Leu Asp Met Leu Arg His  
 35 40 45  
 Leu Tyr Gln Gly Cys Gln Val Val Gln Gly Asn Leu Glu Leu Thr Tyr  
 50 55 60  
 Leu Pro Thr Asn Ala Ser Leu Ser Phe Leu Gln Asp Ile Gln Glu Val  
 65 70 75 80  
 Gln Gly Tyr Val Leu Ile Ala His Asn Gln Val Arg Gln Val Pro Leu  
 85 90 95  
 Gln Arg Leu Arg Ile Val Arg Gly Thr Gln Leu Phe Glu Asp Asn Tyr  
 100 105 110  
 Ala Leu Ala Val Leu Asp Asn Gly Asp Leu Leu Asn Asn Thr Thr Pro  
 115 120 125  
 Val Thr Gly Ala Ser Pro Gly Gly Leu Arg Glu Leu Gln Leu Arg Ser  
 130 135 140  
 Leu Thr Glu Ile Leu Lys Gly Gly Val Leu Ile Gln Arg Asn Pro Gln  
 145 150 155 160  
 Leu Cys Tyr Gln Asp Thr Ile Leu Trp Lys Asp Ile Phe His Lys Asn  
 165 170 175  
 Asn Gln Leu Ala Leu Thr Leu Ile Asp Thr Asn Arg Ser Arg Ala Cys  
 180 185 190  
 His Pro Cys Ser Pro Val Cys Lys Gly Ser Arg Cys Trp Gly Glu Ser

195	200	205
Ser Glu Asp Cys Gln Ser Leu	Thr Arg Thr Val	Cys Ala Gly Gly Cys
210	215	220
Ala Arg Cys Lys Gly Pro Leu Pro Thr Asp Cys Cys His Glu Gln Cys		
225	230	235
Ala Ala Gly Cys Thr Gly Pro Lys His Ser Asp Cys Leu Ala Cys Leu		
245	250	255
His Phe Asn His Ser Gly Ile Cys Glu Leu His Cys Pro Ala Leu Val		
260	265	270
Thr Tyr Asn Thr Asp Thr Phe Glu Ser Met Pro Asn Pro Glu Gly Arg		
275	280	285
Tyr Thr Phe Gly Ala Ser Cys Val Thr Ala Cys Pro Tyr Asn Tyr Leu		
290	295	300
Ser Thr Asp Val Gly Ser Cys Thr Leu Val Cys Pro Leu His Asn Gln		
305	310	315
Glu Val Thr Ala Glu Asp Gly Thr Gln Arg Cys Glu Lys Cys Ser Lys		
325	330	335
Pro Cys Ala Arg Val Cys Tyr Gly Leu Gly Met Glu His Leu Arg Glu		
340	345	350
Val Arg Ala Val Thr Ser Ala Asn Ile Gln Glu Phe Ala Gly Cys Lys		
355	360	365
Lys Ile Phe Gly Ser Leu Ala Phe Leu Pro Glu Ser Phe Asp Gly Asp		
370	375	380
Pro Ala Ser Asn Thr Ala Pro Leu Gln Pro Glu Gln Leu Arg Val Phe		
385	390	395
Glu Thr Leu Glu Ile Thr Gly Tyr Leu Tyr Ile Ser Ala Trp Pro		
405	410	415
Asp Ser Leu Pro Asp Leu Ser Val Leu Gln Asn Leu Gln Val Ile Arg		
420	425	430
Gly Arg Ile Leu His Asn Gly Ala Tyr Ser Leu Thr Leu Gln Gly Leu		
435	440	445
Gly Ile Ser Trp Leu Gly Leu Arg Ser Leu Arg Glu Leu Gly Ser Gly		
450	455	460
Leu Ala Leu Ile His His Asn Thr Arg Leu Cys Phe Val His Thr Val		
465	470	475
Pro Trp Asp Gln Leu Phe Arg Asn Pro His Gln Ala Leu Leu His Thr		
485	490	495
Ala Asn Arg Pro Glu Asp Glu Cys Val Gly Glu Gly Leu Ala Cys His		
500	505	510
Gln Leu Cys Ala Arg Gly His Cys Trp Gly Pro Gly Pro Thr Gln Cys		
515	520	525
Val Asn Cys Ser Gln Phe Leu Arg Gly Gln Glu Cys Val Glu Glu Cys		
530	535	540
Arg Val Leu Gln Gly Leu Pro Arg Glu Tyr Val Asn Ala Arg His Cys		
545	550	555
Leu Pro Cys His Pro Glu Cys Gln Pro Gln Asn Gly Ser Val Thr Cys		
565	570	575
Phe Gly Pro Glu Ala Asp Gln Cys Val Ala Cys Ala His Tyr Lys Asp		
580	585	590
Pro Pro Phe Cys Val Ala Arg Cys Pro Ser Gly Val Lys Pro Asp Leu		
595	600	605
Ser Tyr Met Pro Ile Trp Lys Phe Pro Asp Glu Glu Gly Thr Cys Gln		
610	615	620
Ser Cys Pro Ile Asn Cys Thr His Ser Cys Val Asp Leu Asp Asp Lys		
625	630	635
Gly Cys Pro Ala Glu Gln Arg Ala Ser Pro Leu Thr Ser Ile Ile Ser		
645	650	655
Ala Val Val Gly Ile Leu Leu Val Val Leu Gly Val Val Phe Gly		
660	665	670
Ile Leu Ile Lys Arg Arg Gln Gln Lys Ile Arg Lys Tyr Thr Met Arg		
675	680	685
Arg Leu Leu Gln Glu Thr Glu Leu Val Glu Pro Leu Thr Pro Ser Gly		
690	695	700
Ala Met Pro Asn Gln Ala Gln Met Arg Ile Leu Lys Glu Thr Glu Leu		

705	710	715	720
Arg Lys Val Lys Val Leu Gly Ser Gly Ala Phe Gly Thr Val Tyr Lys			
725	730	735	
Gly Ile Trp Ile Pro Asp Gly Glu Asn Val Lys Ile Pro Val Ala Ile			
740	745	750	
Lys Val Leu Arg Glu Asn Thr Ser Pro Lys Ala Asn Lys Glu Ile Leu			
755	760	765	
Asp Glu Ala Tyr Val Met Ala Gly Val Gly Ser Pro Tyr Val Ser Arg			
770	775	780	
Leu Leu Gly Ile Cys Leu Thr Ser Thr Val Gln Leu Val Thr Gln Leu			
785	790	795	800
Met Pro Tyr Gly Cys Leu Leu Asp His Val Arg Glu Asn Arg Gly Arg			
805	810	815	
Leu Gly Ser Gln Asp Leu Leu Asn Trp Cys Met Gln Ile Ala Lys Gly			
820	825	830	
Met Ser Tyr Leu Glu Asp Val Arg Leu Val His Arg Asp Leu Ala Ala			
835	840	845	
Arg Asn Val Leu Val Lys Ser Pro Asn His Val Lys Ile Thr Asp Phe			
850	855	860	
Gly Leu Ala Arg Leu Leu Asp Ile Asp Glu Thr Glu Tyr His Ala Asp			
865	870	875	880
Gly Gly Lys Val Pro Ile Lys Trp Met Ala Leu Glu Ser Ile Leu Arg			
885	890	895	
Arg Arg Phe Thr His Gln Ser Asp Val Trp Ser Tyr Gly Val Thr Val			
900	905	910	
Trp Glu Leu Met Thr Phe Gly Ala Lys Pro Tyr Asp Gly Ile Pro Ala			
915	920	925	
Arg Glu Ile Pro Asp Leu Leu Glu Lys Gly Glu Arg Leu Pro Gln Pro			
930	935	940	
Pro Ile Cys Thr Ile Asp Val Tyr Met Ile Met Val Lys Cys Trp Met			
945	950	955	960
Ile Asp Ser Glu Cys Arg Pro Arg Phe Arg Glu Leu Val Ser Glu Phe			
965	970	975	
Ser Arg Met Ala Arg Asp Pro Gln Arg Phe Val Val Ile Gln Asn Glu			
980	985	990	
Asp Leu Gly Pro Ala Ser Pro Leu Asp Ser Thr Phe Tyr Arg Ser Leu			
995	1000	1005	
Leu Glu Asp Asp Asp Met Gly Asp Leu Val Asp Ala Glu Glu Tyr Leu			
1010	1015	1020	
Val Pro Gln Gln Gly Phe Phe Cys Pro Asp Pro Ala Pro Gly Thr Gly			
1025	1030	1035	1040
Gly Met Val His His Arg Ser Ser Ser Thr Arg Ser Gly Gly			
1045	1050	1055	
Gly Asp Leu Thr Leu Gly Leu Glu Pro Ser Glu Glu Ala Pro Arg			
1060	1065	1070	
Ser Pro Arg Ala Pro Ser Glu Gly Thr Gly Ser Asp Val Phe Asp Gly			
1075	1080	1085	
Asp Leu Gly Met Gly Ala Ala Lys Gly Leu Gln Ser Leu Pro Ala His			
1090	1095	1100	
Asp Pro Ser Pro Leu Gln Arg Tyr Ser Glu Asp Pro Thr Val Pro Leu			
1105	1110	1115	1120
Pro Ser Glu Thr Asp Gly Tyr Val Ala Pro Leu Thr Cys Ser Pro Gln			
1125	1130	1135	
Pro Glu Tyr Val Asn Gln Pro Asp Val Arg Pro Gln Pro Pro Ser Pro			
1140	1145	1150	
Gln Glu Gly Pro Leu Ser Pro Ala Arg Pro Thr Gly Ala Thr Leu Glu			
1155	1160	1165	
Arg Pro Lys Thr Leu Ser Pro Gly Lys Asn Gly Val Val Lys Asp Val			
1170	1175	1180	
Phe Ala Phe Gly Gly Ala Val Glu Asn Pro Glu Tyr Leu Ala Pro Arg			
1185	1190	1195	1200
Gly Gly Ala Ala Pro Gln Pro His Leu Pro Pro Ala Phe Ser Pro Ala			
1205	1210	1215	
Phe Asp Asn Leu Tyr Tyr Trp Asp Gln Asp Pro Ser Glu Arg Gly Ala			

1220 1225 1230  
Pro Pro Ser Thr Phe Lys Gly Thr Pro Thr Ala Glu Asn Pro Glu Tyr  
1235 1240 1245  
Leu Gly Leu Asp Val Pro Val  
1250 1255

<210> 3  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> PCR Primer

<400> 3  
agccatgggg ccggagccgc a

21

<210> 4  
<211> 26  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> PCR Primer

<400> 4  
agggctgggc agtgcagctc acagat

26

<210> 5  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> PCR Primer

<400> 5  
ctgcgggagc tgcagcttcg aag

23

<210> 6  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> PCR Primer

<400> 6  
ccaaagatct tcttgagcc

20

<210> 7  
<211> 26  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> PCR Primer

<400> 7  
atctgtgagc tgcactgccc agccct

26

<210> 8  
<211> 19

<212> DNA  
<213> Artificial Sequence

<220>  
<223> PCR Primer

<400> 8  
gagcgcagcc ccagccagc

19

<210> 9  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> PCR Primer

<400> 9  
ggctgcaaga agatctttgg

20

<210> 10  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> PCR Primer

<400> 10  
tgggtgcagt tcatggggca

20

<210> 11  
<211> 44  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> PCR Primer

<400> 11  
ccagtttaaa cattaaatg ccgccaccat ggagctggcg gcct

44

<210> 12  
<211> 26  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> PCR Primer

<400> 12  
tgctgggttc caggccccac ccagtg

26

<210> 13  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> PCR Primer

<400> 13  
tcaggatct cccgggctgg gat

23

<210> 14  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> PCR Primer

<400> 14  
gtggaggaat gccgagtact gcag

24

<210> 15  
<211> 39  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> PCR Primer

<400> 15  
tgcgtttcc ctcaacacgg cgatggccac tggaatttt

39

<210> 16  
<211> 39  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> PCR Primer

<400> 16  
aaaattccag tggccatcgc cgtgttgagg gaaaacaca

39

<210> 17  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> PCR Primer

<400> 17  
ctgggcatct gcctgacatc cac

23

<210> 18  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> PCR Primer

<400> 18  
ggtttcaggg acagtctctg aa

22

<210> 19  
<211> 32  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> PCR Primer

<400> 19

gccgtcgact ttacatggca cgtccagacc ca	32
<210> 20	
<211> 18	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> PCR Primer	
<400> 20	
cttcatgtct gtgcgggt	18
<210> 21	
<211> 22	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> PCR Primer	
<400> 21	
ggccggagcc gcagtgagca cc	22
<210> 22	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> PCR Primer	
<400> 22	
cttcgaagct gcagctcccg cag	23
<210> 23	
<211> 25	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> PCR Primer	
<400> 23	
atggagctgg cggcattgtg ccgtt	25
<210> 24	
<211> 18	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> PCR Primer	
<400> 24	
accggcacag acatgaag	18
<210> 25	
<211> 26	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> PCR Primer	

<400> 25	
cactgggtgg gcccctggacc ccagca	26
<210> 26	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> PCR Primer	
<400> 26	
gatccaagca ctttcacccctt cct	23
<210> 27	
<211> 19	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> PCR Primer	
<400> 27	
gctggctggg gctgcgctc	19
<210> 28	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> PCR Primer	
<400> 28	
gggatccaga tgcccttgta gac	23
<210> 29	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> PCR Primer	
<400> 29	
tgcggccatca actgcacccca	20
<210> 30	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> PCR Primer	
<400> 30	
gtggatgtca ggcagatgcc cag	23
<210> 31	
<211> 23	
<212> DNA	
<213> Artificial Sequence	

<220>  
<223> PCR Primer  
  
<400> 31  
aggaaggta aggtgcttgg atc 23  
  
<210> 32  
<211> 26  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> PCR Primer  
  
<400> 32  
taaggtttgg ccccaaaaagt catcag 26  
  
<210> 33  
<211> 23  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> PCR Primer  
  
<400> 33  
gtctacaagg gcatctggat ccc 23  
  
<210> 34  
<211> 23  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> PCR Primer  
  
<400> 34  
ggctgggggc tgcaggtcag ggg 23  
  
<210> 35  
<211> 26  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> PCR Primer  
  
<400> 35  
ctgatgactt ttggggccaa acctta 26  
  
<210> 36  
<211> 22  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> PCR Primer  
  
<400> 36  
ttctgcggac ttggcattct gg 22  
  
<210> 37  
<211> 23  
<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 37

atccccagccc gggagatccc tga

23

<210> 38

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 38

tggcagggttc ccctgga

17

<210> 39

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 39

cccttgacct gcagccccca gcc

23

<210> 40

<211> 3768

<212> DNA

<213> Rhesus Monkey

<220>

<221> misc\_feature

<222> (1)...(3768)

<223> R = A or G

<221> misc\_feature

<222> (1)...(3768)

<223> Y = C or T

<400> 40

atggagctgg	cggcctggta	ccgctggggg	ctccctcctcg	ccctcttgcc	ccccggagct	60
gcgggcaccc	aagtgtcac	cggcacagac	atgaagctgc	ggctccotgc	cagtcccgag	120
acccacactgg	acatgtctcg	ccacactctac	cagggtgtcc	aggtggtgca	gggtaacctg	180
gaactcacct	acctgcccac	aatgccagc	ctctcccttc	tgcaggatata	ccaggagggtg	240
cagggtctacg	tgctoatcgc	tcacaaccaa	gtgaggcagg	tcccactgca	gaggctgcgg	300
attgtgcgag	gcaccacagct	ctttgaggac	aactatgccc	tggccgtgct	agacaatgga	360
gaccggctga	acaataccac	ccctgtcaca	ggggctcc	caggaggct	gcgggagctg	420
cagcttcgaa	gcctcacaga	gatcttggaa	ggagggggtct	tgatccagcg	gaaccccccag	480
ctctgttacc	aggacacgtt	tttgttggaa	gacatcttcc	ataagaacaa	ccagctggct	540
ctcacactga	tcgacaccaa	ccgctctcg	gcctgccacc	cctgttctcc	agtgtgttaag	600
ggctcccgct	gtggggaga	gagttcttgag	gattgtcaga	gcctgacgcg	cactgtctgt	660
gcccggctgg	gtgcccgtc	caagggggca	ctgcccactg	actgctgcca	tgagcagtgt	720
gtgtccggct	gcacggggccc	caagcactct	gactgcctgg	cctgcctcca	ttcaaccac	780
agcggcatct	gtgarctgca	ctgcccagcc	ctggcacct	acaacacaga	cacctttgag	840
tccatggcca	accccgagggg	ccggatataca	tgcggccca	gctgtgtgac	tgcctgtccc	900
tacaactacc	tttctacgg	cgtggatcc	tgcacccctcg	tctgccccct	gcacaaccaa	960
gagggtgacag	cgaggacgg	aacacagcga	tgtgagaagt	gcagcaagcc	ctgtgcccga	1020
gtgtgctatg	gtctgggcat	ggagcacttg	cgagagggtg	ggccgggtcac	cagtgccaat	1080
atccaggagt	ttgtctggctg	caagaagatc	tttgggagyt	tggcatttct	gccagagago	1140

tttatggcg acccagcctc caacaccgcc ccgttcagc cggagcagct ccgagtgtt 1200  
 gagactctgg aagagatcac aggttaccta tacatctcag catggccaga cagcctgcct 1260  
 gaccttagcg tcctccagaa cctgcaagta atccggggac gaattctgca caatggcgcc 1320  
 tactcaactga ccctgcaagg gctgggcata agctggctgg ggctgcgcgc gctgagggaa 1380  
 ctgggcagtg gactggccct catccaccat aacaccgcgc tctgcttgt gcacacggtg 1440  
 ccctgggacc agctcttcg gaaccgcac caagccctgc tccacactgc caaccggcca 1500  
 gaggacgagt gtgtggcga gggcctggcc tgccaccagc tgtgcggccr agggcactgc 1560  
 tgggtccag ggcccaccca gtgtgtcaac tgccagccagt tccttcgggg ccaggagtgc 1620  
 gtggaggaat gcccggact gcaggggctc cccagggagt atgtgaatgc cagacactgt 1680  
 ttgccgtgcc accctgagtg tcagccccag aatggctcag tgacatgtt tggaccggag 1740  
 gctgaccagt gtgtggcctg tgcccaactat aaggaccctc ccttctgcgt ggcccgctgc 1800  
 cccagcggtg tgaaaacctga cctctccat atgcccattt ggaagttcc agatgaggag 1860  
 ggcacgtgcc agcctgccc catcaactgc accactctt gtgtggacct ggtgacaag 1920  
 ggctgccccg ccgagcagar agccagccct ctgacgtcca tcatctctgc tgggtggc 1980  
 attctgtgg tcgtggctt ggggtggc tttggaatcc tcatcaagcg acggcagcag 2040  
 aagatccgga agtacacgat gcccggctg ctgcaggaaa cggagctggg ggagccactg 2100  
 acaccgagtg gagcgtatgcc caaccaggcg cagatgcggg tcctgaaaga gacggagctg 2160  
 aggaaggtga aggtgcttgg atctggagct tttggcacag tctacaaggg catctggatc 2220  
 cctgtatgggg agaatgtgaa aattccagtg gccatcaaag tggtagggaa aaacacatcc 2280  
 cccaaagcca acaaagaat cttagacgaa gcatatgtga tatgtctccc gcctcctggg catctgcctg acatccacgg tggctgggtg gggctccca 2340  
 atgcccattt gctgcctt agaccatgtc cgagaaaacc atgcccattt gctacctggaa gggctccca 2400  
 gaccgtctga actgtgttat gcaatttgc aaggggatga tggtagggaa ggttgcgg 2460  
 ctcgtacaca gggacttggc tgctcgaaac gtgtggtca attacagact ttgggcttgc tcggctgtg gacattgacg tggtagggaa ggttgcgg 2520  
 gggggcaagg tgcccatcaa gtggatggcg ctggagttca caccagagtg atgtgtggag ttatggtgc actgtgtggg agatcccaa ccatgtcaaa 2580  
 aaaccttacg atgggatccc agcccgggag atccctgacc ctgcccagc ccccatctg caccattgtat gtctacatga attgactctg aatgtcgcc gagattccgg gagttgggtt agacagagta ccatgcagat 2640  
 agggacccccc agcgctttgt ggtcatccag aatgaggact ttcccgacg ggggttcacc 2700  
 gacagcacct tctaccgctc actgtgtggag gacgatgaca gggggcaagg tgcccatcaa gtggatggcg ctggagttca agctgatgac tttggggcc 2760  
 gaggagtata tggtacccca gcagggttcc ttctgtccag ggcatggtcc accacaggca ccgcagctca tctaccagga cttagggctgg agccctctga agaggaggcc cccaggtctc actggctctg atgtattga tggtagccctt ggaatggggg tggtagggaa gggggagcgg 2820  
 ctccccgcac atgacccag ccctctacag cggtagtgc cttctgtgaga ctgacggcta cggtggccccc ctgacctgc aaccatgtgc 2880  
 aaccagccag atgttgcggc acagccccc tcggcccaag cggacccatctc cggtagtgc 2940  
 cgacctactg gtgcactct gggaaaggccc aagactctct tggtagggaa ggttgcgg 2980  
 gtcaaagacg ttttgcctt tgggggtgct gtggagaacc gggggccctct gtttgcgg 3040  
 ggaggagctg cccctcagcc ccacccctt cctgccttca tggtagggaa ggttgcgg 3100  
 tattactggg accaggaccc atcagagcgg ggggtccac cccaggtctt ggggtccac cccaggtctt ggggtccac 3160  
 cctacggcag agaaccaggaa gtacctgggt ctggacgtgc cggtagtgc 3220  
 cggtagtactt ggcaccccggtt ggggtccac 3280  
 cccaggtctt ggggtccac 3340  
 cggtagtactt ggcaccccggtt ggggtccac 3400  
 cccaggtctt ggggtccac 3460  
 cggtagtactt ggcaccccggtt ggggtccac 3520  
 cccaggtctt ggggtccac 3580  
 cggtagtactt ggcaccccggtt ggggtccac 3640  
 cccaggtctt ggggtccac 3700  
 cggtagtactt ggcaccccggtt ggggtccac 3768

<210> 41  
 <211> 1255  
 <212> PRT  
 <213> Rhesus Monkey

<220>  
 <221> VARIANT  
 <222> 517  
 <223> Xaa = Q or R

<221> VARIANT  
 <222> 647  
 <223> Xaa = K or R

<221> VARIANT  
 <222> 1075  
 <223> Xaa = Q or R

<400> 41

Met Glu Leu Ala Ala Trp Tyr Arg Trp Gly Leu Leu Leu Ala Leu Leu  
 1 5 10 15  
 Pro Pro Gly Ala Ala Gly Thr Gln Val Cys Thr Gly Thr Asp Met Lys  
 20 25 30  
 Leu Arg Leu Pro Ala Ser Pro Glu Thr His Leu Asp Met Leu Arg His  
 35 40 45  
 Leu Tyr Gln Gly Cys Gln Val Val Gln Gly Asn Leu Glu Leu Thr Tyr  
 50 55 60  
 Leu Pro Thr Asn Ala Ser Leu Ser Phe Leu Gln Asp Ile Gln Glu Val  
 65 70 75 80  
 Gln Gly Tyr Val Leu Ile Ala His Asn Gln Val Arg Gln Val Pro Leu  
 85 90 95  
 Gln Arg Leu Arg Ile Val Arg Gly Thr Gln Leu Phe Glu Asp Asn Tyr  
 100 105 110  
 Ala Leu Ala Val Leu Asp Asn Gly Asp Pro Leu Asn Asn Thr Thr Pro  
 115 120 125  
 Val Thr Gly Ala Ser Pro Gly Gly Leu Arg Glu Leu Gln Leu Arg Ser  
 130 135 140  
 Leu Thr Glu Ile Leu Lys Gly Gly Val Leu Ile Gln Arg Asn Pro Gln  
 145 150 155 160  
 Leu Cys Tyr Gln Asp Thr Ile Leu Trp Lys Asp Ile Phe His Lys Asn  
 165 170 175  
 Asn Gln Leu Ala Leu Thr Leu Ile Asp Thr Asn Arg Ser Arg Ala Cys  
 180 185 190  
 His Pro Cys Ser Pro Val Cys Lys Gly Ser Arg Cys Trp Gly Glu Ser  
 195 200 205  
 Ser Glu Asp Cys Gln Ser Leu Thr Arg Thr Val Cys Ala Gly Gly Cys  
 210 215 220  
 Ala Arg Cys Lys Gly Pro Leu Pro Thr Asp Cys Cys His Glu Gln Cys  
 225 230 235 240  
 Ala Ala Gly Cys Thr Gly Pro Lys His Ser Asp Cys Leu Ala Cys Leu  
 245 250 255  
 His Phe Asn His Ser Gly Ile Cys Glu Leu His Cys Pro Ala Leu Val  
 260 265 270  
 Thr Tyr Asn Thr Asp Thr Phe Glu Ser Met Pro Asn Pro Glu Gly Arg  
 275 280 285  
 Tyr Thr Phe Gly Ala Ser Cys Val Thr Ala Cys Pro Tyr Asn Tyr Leu  
 290 295 300  
 Ser Thr Asp Val Gly Ser Cys Thr Leu Val Cys Pro Leu His Asn Gln  
 305 310 315 320  
 Glu Val Thr Ala Glu Asp Gly Thr Gln Arg Cys Glu Lys Cys Ser Lys  
 325 330 335  
 Pro Cys Ala Arg Val Cys Tyr Gly Leu Gly Met Glu His Leu Arg Glu  
 340 345 350  
 Val Arg Ala Val Thr Ser Ala Asn Ile Gln Glu Phe Ala Gly Cys Lys  
 355 360 365  
 Lys Ile Phe Gly Ser Leu Ala Phe Leu Pro Glu Ser Phe Asp Gly Asp  
 370 375 380  
 Pro Ala Ser Asn Thr Ala Pro Leu Gln Pro Glu Gln Leu Arg Val Phe  
 385 390 395 400  
 Glu Thr Leu Glu Ile Thr Gly Tyr Leu Tyr Ile Ser Ala Trp Pro  
 405 410 415  
 Asp Ser Leu Pro Asp Leu Ser Val Leu Gln Asn Leu Gln Val Ile Arg  
 420 425 430  
 Gly Arg Ile Leu His Asn Gly Ala Tyr Ser Leu Thr Leu Gln Gly Leu  
 435 440 445  
 Gly Ile Ser Trp Leu Gly Leu Arg Ser Leu Arg Glu Leu Gly Ser Gly  
 450 455 460  
 Leu Ala Leu Ile His His Asn Thr Arg Leu Cys Phe Val His Thr Val  
 465 470 475 480  
 Pro Trp Asp Gln Leu Phe Arg Asn Pro His Gln Ala Leu Leu His Thr  
 485 490 495  
 Ala Asn Arg Pro Glu Asp Glu Cys Val Gly Glu Gly Leu Ala Cys His  
 500 505 510

Gln Leu Cys Ala Xaa Gly His Cys Trp Gly Pro Gly Pro Thr Gln Cys  
 515 520 525  
 Val Asn Cys Ser Gln Phe Leu Arg Gly Gln Glu Cys Val Glu Glu Cys  
 530 535 540  
 Arg Val Leu Gln Gly Leu Pro Arg Glu Tyr Val Asn Ala Arg His Cys  
 545 550 555 560  
 Leu Pro Cys His Pro Glu Cys Gln Pro Gln Asn Gly Ser Val Thr Cys  
 565 570 575  
 Phe Gly Pro Glu Ala Asp Gln Cys Val Ala Cys Ala His Tyr Lys Asp  
 580 585 590  
 Pro Pro Phe Cys Val Ala Arg Cys Pro Ser Gly Val Lys Pro Asp Leu  
 595 600 605  
 Ser Tyr Met Pro Ile Trp Lys Phe Pro Asp Glu Gly Thr Cys Gln  
 610 615 620  
 Pro Cys Pro Ile Asn Cys Thr His Ser Cys Val Asp Leu Asp Asp Lys  
 625 630 635 640  
 Gly Cys Pro Ala Glu Gln Xaa Ala Ser Pro Leu Thr Ser Ile Ile Ser  
 645 650 655  
 Ala Val Val Gly Ile Leu Leu Val Val Val Leu Gly Val Val Phe Gly  
 660 665 670  
 Ile Leu Ile Lys Arg Arg Gln Gln Lys Ile Arg Lys Tyr Thr Met Arg  
 675 680 685  
 Arg Leu Leu Gln Glu Thr Glu Leu Val Glu Pro Leu Thr Pro Ser Gly  
 690 695 700  
 Ala Met Pro Asn Gln Ala Gln Met Arg Ile Leu Lys Glu Thr Glu Leu  
 705 710 715 720  
 Arg Lys Val Lys Val Leu Gly Ser Gly Ala Phe Gly Thr Val Tyr Lys  
 725 730 735  
 Gly Ile Trp Ile Pro Asp Gly Glu Asn Val Lys Ile Pro Val Ala Ile  
 740 745 750  
 Lys Val Leu Arg Glu Asn Thr Ser Pro Lys Ala Asn Lys Glu Ile Leu  
 755 760 765  
 Asp Glu Ala Tyr Val Met Ala Gly Val Gly Ser Pro Tyr Val Ser Arg  
 770 775 780  
 Leu Leu Gly Ile Cys Leu Thr Ser Thr Val Gln Leu Val Thr Gln Leu  
 785 790 795 800  
 Met Pro Tyr Gly Cys Leu Leu Asp His Val Arg Glu Asn Arg Gly Arg  
 805 810 815  
 Leu Gly Ser Gln Asp Leu Leu Asn Trp Cys Met Gln Ile Ala Lys Gly  
 820 825 830  
 Met Ser Tyr Leu Glu Asp Val Arg Leu Val His Arg Asp Leu Ala Ala  
 835 840 845  
 Arg Asn Val Leu Val Lys Ser Pro Asn His Val Lys Ile Thr Asp Phe  
 850 855 860  
 Gly Leu Ala Arg Leu Leu Asp Ile Asp Glu Thr Glu Tyr His Ala Asp  
 865 870 875 880  
 Gly Gly Lys Val Pro Ile Lys Trp Met Ala Leu Glu Ser Ile Leu Arg  
 885 890 895  
 Arg Arg Phe Thr His Gln Ser Asp Val Trp Ser Tyr Gly Val Thr Val  
 900 905 910  
 Trp Glu Leu Met Thr Phe Gly Ala Lys Pro Tyr Asp Gly Ile Pro Ala  
 915 920 925  
 Arg Glu Ile Pro Asp Leu Leu Glu Lys Gly Glu Arg Leu Pro Gln Pro  
 930 935 940  
 Pro Ile Cys Thr Ile Asp Val Tyr Met Ile Met Val Lys Cys Trp Met  
 945 950 955 960  
 Ile Asp Ser Glu Cys Arg Pro Arg Phe Arg Glu Leu Val Ser Glu Phe  
 965 970 975  
 Ser Arg Met Ala Arg Asp Pro Gln Arg Phe Val Val Ile Gln Asn Glu  
 980 985 990  
 Asp Leu Gly Pro Ala Ser Pro Leu Asp Ser Thr Phe Tyr Arg Ser Leu  
 995 1000 1005  
 Leu Glu Asp Asp Asp Met Gly Asp Leu Val Asp Ala Glu Glu Tyr Leu  
 1010 1015 1020

Val Pro Gln Gln Gly Phe Phe Cys Pro Asp Pro Ala Pro Gly Thr Gly  
 1025 1030 1035 1040  
 Gly Met Val His His Arg His Ser Ser Ser Thr Arg Ser Gly Gly  
 1045 1050 1055  
 Gly Asp Leu Thr Leu Gly Leu Glu Pro Ser Glu Glu Ala Pro Arg  
 1060 1065 1070  
 Ser Pro Xaa Ala Pro Ser Glu Gly Thr Gly Ser Asp Val Phe Asp Gly  
 1075 1080 1085  
 Asp Leu Gly Met Gly Ala Ala Lys Gly Leu Gln Ser Leu Pro Ala His  
 1090 1095 1100  
 Asp Pro Ser Pro Leu Gln Arg Tyr Ser Glu Asp Pro Thr Val Pro Leu  
 1105 1110 1115 1120  
 Pro Ser Glu Thr Asp Gly Tyr Val Ala Pro Leu Thr Cys Ser Pro Gln  
 1125 1130 1135  
 Pro Glu Tyr Val Asn Gln Pro Asp Val Arg Pro Gln Pro Pro Ser Pro  
 1140 1145 1150  
 Gln Glu Gly Pro Leu Ser Pro Ala Arg Pro Thr Gly Ala Thr Leu Glu  
 1155 1160 1165  
 Arg Pro Lys Thr Leu Ser Pro Gly Lys Asn Gly Val Val Lys Asp Val  
 1170 1175 1180  
 Phe Ala Phe Gly Gly Ala Val Glu Asn Pro Glu Tyr Leu Ala Pro Arg  
 1185 1190 1195 1200  
 Gly Gly Ala Ala Pro Gln Pro His Leu Pro Pro Ala Phe Ser Pro Ala  
 1205 1210 1215  
 Phe Asp Asn Leu Tyr Tyr Trp Asp Gln Asp Pro Ser Glu Arg Gly Ala  
 1220 1225 1230  
 Pro Pro Ser Thr Phe Lys Gly Thr Pro Thr Ala Glu Asn Pro Glu Tyr  
 1235 1240 1245  
 Leu Gly Leu Asp Val Pro Val  
 1250 1255

<210> 42  
 <211> 3768  
 <212> DNA  
 <213> Rhesus Monkey

<400> 42  
 atggagctgg cggcctggta ccgctggggg ctcctcctcg ccctcttgcc ccccgagct 60  
 gccccaccac aagtgtgcac cggcacagac atgaagctgc ggctccctgc cagtccccgag 120  
 acccacctgg acatgctccg ccacactctac cagggtgcc aggtgggtca gggtaacctg 180  
 gaactcacct acctgcccac caatgccagc ctctcccttcc tgcaggatata ccaggagggtg 240  
 cagggctacg tgctcatcgc tcacaaccaa gtgaggcagg tcccactgca gaggtgcgg 300  
 attgtgcagc gcacccagct ctttggggac aactatgccc tggccgtgtc agacaatgga 360  
 gacctgctga acaataccac ccctgtcaca gggccctccc caggaggcct gcgggagctg 420  
 cagcttcgaa gcctcacaga gatcttgaaa ggaggggct tgatccagcg gaaccccccag 480  
 ctctgttacc aggacacgt ttgttggaaag gacatcttcc ataagaacaa ccagctggct 540  
 ctcacactga tcgacaccaa ccgctctcgg gcctgccacc cctgttctcc agtgtgtaaag 600  
 ggctcccgct gctggggaga gagttctgag gattgtcaga gcctgacgcg cactgtctgt 660  
 gccgggtggct gtgcccgtc caagggggcca ctgcccactg actgtgtccca tgagcagtgt 720  
 gctgcccggct gcacggggccca caagcactt gactgcctgg cctgccttcca cttaaccac 780  
 agccggcatct gtgaactgca ctgcccagcc ctggtcaccc acaacacaga caccctttag 840  
 tccatggccca acccccgggg cccgtataca ttccggccca gctgtgtac tgccctgtccc 900  
 tacaactacc ttcttacggc cttggggatcc tgcacccctcg tctgccccct gcacaaccaa 960  
 gaggtgacag cggaggacgg aacacagcga tgtgagaagt gcagcaagcc ctgtgcccga 1020  
 gtgtgtatcg gtctggccat ggagcactt cgaggggtga gggcggtcac cagtgcctat 1080  
 atccaggagt ttgttggctg caagaagatc ttggggatct tggcatttct gccagagagc 1140  
 ttgtatggcg acccagcctc caacaccggc cccgttccgc cggagcagct cegagtgttt 1200  
 gagactctgg aagagatcac aggttaccta tacatctcg catggccaga cagcctgcct 1260  
 gaccttagcg tcctccagaa cctgcaagta atccggggac gaattctgca caatggcgcc 1320  
 tactcaactga ccctgcaagg gctgggcattc agctggctgg ggctgcccgc gctgagggaa 1380  
 ctgggcagtg gactggccct catccaccat aacaccggcc tctgcttgc tgacacgggtg 1440  
 ccctgggacc agctttccg gaacccggcac caagccctgc tccacactgc caacccggca 1500  
 gaggacgagt gtgtggcgaa gggccctggcc tgccaccaggc tgcgccccg agggactgc 1560

tggggtccag	ggcccaccca	gtgtgtcaac	tgcagccagt	tccttcgggg	ccaggagtgc	1620
gtggagaat	gcccgtact	gcaggggctc	cccagggagt	atgtgaatgc	cagacactgt	1680
ttgccgtcc	accctgagtg	tcagccccag	aatggcttag	tgacatgttt	tggaccggag	1740
gctgaccagt	gtgtggctg	tgcccactat	aaggaccctc	ccttctcggt	ggcccgctgc	1800
cccagcggtg	tggaaacctga	cctctcttac	atgcccattct	ggaagtttcc	agatgaggag	1860
ggcacgtgcc	agtcttgc	catcaactgc	acccactct	gtgtggacct	ggatgacaag	1920
ggctgccccg	ccgagcagag	agccagccct	ctgacgtcca	tcatctctgc	tgtgtgggc	1980
attctgtgg	tctgtgttct	gggggtggtc	tttggaatcc	tcatcaagcg	acggcagcag	2040
aagatccgga	agtacacgat	gcccggctg	ctgcaggaaa	cgaggctgg	ggagccactg	2100
acaccggagt	gagcgtgcc	caaccaggcg	cagatgcgga	tcctgaaaga	gacggagctg	2160
aggaagggt	agggtcttg	atctggagct	tttggcacag	tctacaaggg	catctggatc	2220
cctgtatgggg	agaatgtgaa	aattccagtg	gccatcaaag	tgttggaggg	aaacacatcc	2280
cccaaagcca	acaaaagaaat	cttagacgaa	gcatatgtga	tggctgggt	gggctcccca	2340
tatgtctccc	gcctcctggg	catctgcctg	acatccacgg	tgcagctgg	gacacagctt	2400
atgccctatg	gctgcctctt	agaccatgtc	cgagaaaaacc	gcccgcgcct	gggctcccg	2460
gacctgtga	actgggttat	gcagattgcc	aaggggatga	gctacctgg	ggatgtgcgg	2520
ctcgtaaaaa	gggacttggc	tgctcggaa	gtgctggta	agagtcccaa	ccatgtcaaa	2580
attacagact	ttgggctggc	tcggctgctg	gacattgacg	agacagagta	ccatgcagat	2640
gggggcaagg	tgccccatcaa	gtggatggcg	ctggagtc	ttctccgacg	gcccgttacc	2700
caccagagt	atgtgtggag	ttatgtgtg	actgtgtgg	agctgtatgac	ttttggggcc	2760
aaaccttacg	atgggatccc	agccccggag	atccctgacc	tgtggaaaa	gggggagcgg	2820
ctgccccagg	cccccatctg	caccattgt	gtctcatg	tcatgttcaa	atgttggatg	2880
attgactctg	aatgtcgcc	gagattccgg	gagttgtgt	cgaaattctc	ccgcatggcc	2940
agggaccccc	agcgcttgc	ggtcatccag	aatgaggact	tggggccagc	cagtcccttg	3000
gacagcacct	totaccgctc	actgtggag	gacgatgaca	tggggacct	ggtggatgt	3060
gaggagtatc	tggtacccca	gcagggcttc	ttctgtccag	accctggccc	gggcacttgg	3120
ggcatggtcc	accacaggca	ccgcagctca	tctaccagg	gtgggggtgg	ggcactgtacg	3180
ctagggctgg	agccctctga	agaggaggcc	cccaggctc	cacgggcacc	ctccgaaggg	3240
actggctctg	atgtatttga	tggtgaccta	ggaatgggg	cagccaagg	gtgcacaagg	3300
ctccccgcac	atgacccca	ccctctacag	cggtacagtg	aggacccac	gttacccctg	3360
ccttctgaga	ctgacggct	cggtggcccc	ctgacctgca	gtccccagcc	cgaatatgt	3420
aaccagccag	atgttcggcc	acagccccct	tcgccccaa	agggccctct	gtctctgtcc	3480
cgacctactg	gtgccactct	ggaaaggccc	aagactctct	ccccaggaa	aatggggtt	3540
gtcaaagacg	ttttgcctt	tgggggtgt	gtggagaacc	ccgagta	ggcaccccg	3600
ggaggagctg	ccctctagcc	ccaccttct	cctgccttca	gcccagctt	cgacaacctc	3660
tattactggg	accaggaccc	atcagagcgg	ggggctccac	ctagcacctt	caaaggaca	3720
cctacggcag	agaacccaga	gtacctgggt	ctggacgtgc	cagtgtga		3768

<210> 43

<211> 3768

<212> DNA

<213> Rhesus Monkey

<400> 43

atggagctgg	cggcctggta	ccgctggggg	ctcctcctcg	ccctcttgc	ccccggagct	60
gcgggcaccc	aagtgtcac	cggcacagac	atgaagctgc	ggctccctgc	cagtcccgag	120
acccacactgg	acatgctccg	ccacccctac	cagggctgcc	aggtgggtca	gggtaacctg	180
gaactcacct	acctgcccac	caatgccage	ctctccttcc	tgcaggatat	ccaggagggtg	240
cagggctacg	tgtctcatcgc	tcacaaccaa	gtgaggcagg	tcccactgca	gaggctgcgg	300
atttgtcgag	gcacccagct	cttgaggac	aactatgccc	tggccgtgct	agacaatgga	360
gacctgctga	acaataccac	ccctgtcaca	ggggcctccc	caggaggcct	gcgggagctg	420
cagcttcgaa	gcctcacaga	gatctgaaa	ggaggggtct	tgatccagcg	gaaccccccag	480
ctctgttacc	aggacacgat	tttggaaag	gacatcttcc	ataagaacaa	ccagctggct	540
ctcacactga	tgcacaccaa	ccgctctcgg	gcctgcccacc	cctgttctcc	agtgtgtaa	600
ggctcccgct	gctggggaga	gagttcttag	gattgtcaga	gcctgacgcg	cactgtctgt	660
gcccgtggct	gtgcccgtg	caaggggcca	ctgcccactg	actgtctgcca	tgagcagtgt	720
gctggccggct	gcacggggccc	caagcaactt	gactgtcctgg	cctgcctcca	cttcaaccac	780
agcggcatct	gtgagctgca	ctgcccagcc	ctggtcacat	acaacacaga	cacccctttag	840
tccatgcccc	accccgaggg	ccggatatac	ttcgccgc	gctgtgtac	tgcctgtccc	900
tacaactacc	tttctacgg	cgtggatcc	tgcaccctcg	tctggcccc	gcacaaccaa	960
gaggtgacag	cgaggagacgg	aacacagcg	tgtgagaagt	gcagaagcc	ctgtgcccga	1020
gtgtgctatg	gtctggcat	ggagcacttg	cgagaggtga	gggcggtcac	cagtgcctaat	1080
atccaggagt	ttgctggctg	caagaagatc	tttggagact	tggcatttct	gccagagagc	1140
tttgcattggcg	acccagcctc	caacacccg	ccgcttcagc	cgaggacqct	ccqagttdt	1200

gagactctgg aagagatcac aggttaccta tacatctcag catggccaga cagcctgcct 1260  
 gaccttagcg tcctccagaa cctgcaagta atccggggac gaattotgca caatggcgcc 1320  
 tactcaactga ccctgcaagg gctggcatac agctggctgg ggctgcgctc gotgagggaa 1380  
 ctgggcagtg gactggccct catccaccat aacacccgccc tctgctttgt gcacacggtg 1440  
 ccctgggacc agctcttccg gaacccgcac caagccctgc tccacactgc caaccggcca 1500  
 gaggacgagt gtgtggcga gggcctgccc tgccaccagc tgtgcgccc agggcactgc 1560  
 tggggtccag ggcccaccca gtgtgtcaac tgcagccagt tccctcgcccc ccaggagtgc 1620  
 gtggaggaat gccgagact gcaggggctc cccagggagt atgtaatgc cagacactgt 1680  
 ttgcgtgcc accctgagtg tcagccccc aatggctcag tgacatgtt tgacccggag 1740  
 gctgaccagt gtgtggctg tgcccaactat aagaccctc ccttctcggt gccccgctgc 1800  
 cccagcggtg tgaaacctga cctctccatc atgcccattt ggaagttcc agatgaggag 1860  
 ggcacgtgcc agtcttgc catcaactgc accaccctt gtgtggaccc ggtatgacaag 1920  
 ggctgccccg ccgagcagag agccagccct ctgacgtcca tcatctctgc tgggtgggc 1980  
 attctgtgg tcgtgttgc tgggggtgtc tttggatcc tcatcaagcg acggcagcag 2040  
 aagatccgga agtacacgat gcccggggctg ctgcaggaaa cggagctggt ggagccactg 2100  
 acaccgagtg gaggcgtgcc caaccaggcg cagatggca tcttggaaaga gacggagctg 2160  
 aggaaggtga aggtgttgg atctggagct tttggcacag tctacaaggg catctggatc 2220  
 cctgtgggg agaatgtgaa aattccagtg gccatcaaag tgggggtgtt ggctccccca 2280  
 cccaaagcca acaaagaaat cttagacgaa gcatatgtga tggctgggtt gacacagctt 2340  
 tatgtctccc gcctcctggg catctgcctg acatccacgg tgcagctgtt gacacagctt 2400  
 atgccttatg gtcgtctt agaccatgtc cgagaaaaacc gcccggccct gggctccag 2460  
 gacctgtga actgggttat gcagattgcc aaggggatga gctacctgga ggtatgtgcgg 2520  
 ctcgtacaca gggacttggc tgctcggAAC gtgtgtgtca agagtcccaa ccatgtcaaa 2580  
 attacagact ttgggtggc tcggctgtt gacattgacg agacagagta ccatgcagat 2640  
 gggggcaagg tgcccatcaa gtggatggcg ctggagtcac ttctccgacg ggggttcacc 2700  
 caccagagtg atgtgtggag ttatgggtgt actgtgtggg agctgtatgac ttttggggcc 2760  
 aaaccttaeg atgggatccc agcccgggag atccctgacc tgctggaaaa gggggagcgg 2820  
 ctgccccagc ccccatctg caccattgtt gtctacatga tcatggtcaa atgttggatg 2880  
 attgactctg aatgtcgcc gagattccgg gagttgggtt cggaattctc ccgcattggcc 2940  
 agggacccccc agcgctttgt ggtcatccag aatgaggact tggggccagc cagtcccttg 3000  
 gacagcacct tctaccgctc actgtgtggag gacgatgaca tgggggaccc ggtggatgct 3060  
 gaggagtatc ttgttaccca gcagggttcc ttctgtccag accctggccc gggcactggg 3120  
 ggcatggtcc accacaggca ccccgatctc tctaccggaa gtggcggtgg ggacctgacg 3180  
 ctagggtgg agccctctga agaggaggcc cccagggttcc cacgggcacc ctcggaaagg 3240  
 actggctctg atgtatgttga ttgtgaccta ggaatggggg cagccaaggg gctgcaaagc 3300  
 ctccccgcac atgaccccaag ccctctacag cggtagtgcg aggacccac ggtacccctg 3360  
 ccttctgaga ctgacggctt cgttggccccc ctgacctgcgtt gtcggccagcc cgaatatgtg 3420  
 aaccagccag atgttcggcc acagccccct tcgcccccaag agggccctct gtctcctgccc 3480  
 cgacctactg gtgcactctt gaaaaggccc aagactctt ccccaaggaa gaatggggtt 3540  
 gtcaaagacg ttttgcctt tgggggtgtt gtggagaacc cccgactt cgcaccccg 3600  
 ggaggagctg cccctcagcc ccacccctt cctgccttca gcccacgcctt cgacaaacctc 3660  
 tattactggg accaggaccc atcagagcgg ggggctccac ttagcacctt caaaggaca 3720  
 cctacggcag agaaccacca gtaacctgggt ctggacgtgc cagtgtga 3768

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>					
IPC 7	C12N15/12	C12N15/861	C12N5/16	C07K14/71	C12P21/02
	A61K38/17	A61K48/00			

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, SEQUENCE SEARCH, BIOSIS, MEDLINE, EMBASE

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 02/14503 A (HAND ZIMMERMANN SUSAN ;CORIXA CORP (US); FOY TERESA M (US); KALOS) 21 February 2002 (2002-02-21) page 3, line 1 -page 6, line 9 page 9, line 14 -page 14, line 10 page 38, line 12 -page 41, line 4 page 56, line 22 -page 83, line 29; example 1 Sequence Listing: SEQ ID NOS: 1 and 2 ----	1-20
Y	WO 02/13847 A (HAND ZIMMERMANN SUSAN ;CORIXA CORP (US); CHEEVER MARTIN A (US); GA) 21 February 2002 (2002-02-21) page 2, line 9 -page 4, line 13 page 6, line 4 -page 17, line 11 page 23, line 15 -page 34, line 3 Sequence Listing: SEQ ID NOS: 1 and 2 ----	1-20 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

27 May 2004

Date of mailing of the international search report

04/06/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Donath, C

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5 869 445 A (DISIS MARY L ET AL) 9 February 1999 (1999-02-09) column 2, line 25 -column 3, line 12 column 6, line 27 - line 53; example 4 Sequence Listing: SEQ ID NOS: 1 and 2 ----	1-20
A	FENDLY B M ET AL: "SUCCESSFUL IMMUNIZATION OF RHESUS MONKEYS WITH THE EXTRACELLULAR DOMAIN OF P185HER2: A POTENTIAL APPROACH TO HUMAN BREAST CANCER" VACCINE RESEARCH, MARY ANN LIEBERT, INC., PUBLISHERS, US, vol. 2, no. 3, 1993, pages 129-139, XP009030428 abstract ----	1-20
A	DISIS M L ET AL: "HER-2/NEU PROTEIN: A TARGET FOR ANTIGEN-SPECIFIC IMMUNOTHERAPY OF HUMAN CANCER" ADVANCES IN CANCER RESEARCH, ACADEMIC PRESS, LONDON, GB, vol. 71, 1991, pages 343-371, XP000982776 ISSN: 0065-230X the whole document ----	1-20
A	HUNG M-C ET AL: "HER-2/NEU-TARGETING GENE THERAPY - A REVIEW" GENE, ELSEVIER BIOMEDICAL PRESS. AMSTERDAM, NL, vol. 159, no. 2, 1995, pages 65-71, XP002057855 ISSN: 0378-1119 the whole document -----	1-20

**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  

Although claims 8-11 and 14-20 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2.  Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.  Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 0214503	A	21-02-2002	AU CA EP NO WO US	9500801 A 2419533 A1 1366153 A2 20030714 A 0214503 A2 2002193329 A1		25-02-2002 21-02-2002 03-12-2003 11-04-2003 21-02-2002 19-12-2002
WO 0213847	A	21-02-2002	AU WO US	8336001 A 0213847 A2 2003157119 A1		25-02-2002 21-02-2002 21-08-2003
US 5869445	A	09-02-1999	US US AU AU BR CA CN CZ EP EP HU JP NO NZ WO US US US US US	5801005 A 2002019331 A1 708237 B2 5522296 A 9607889 A 2216601 A1 1183117 A 9703096 A3 1418235 A2 0817846 A1 9801826 A2 11502710 T 974502 A 306616 A 9630514 A1 2002055614 A1 6075122 A 5726023 A 5876712 A 5846538 A 2004082758 A1		01-09-1998 14-02-2002 29-07-1999 16-10-1996 10-08-1999 03-10-1996 27-05-1998 14-01-1998 12-05-2004 14-01-1998 30-11-1998 09-03-1999 27-11-1997 30-03-2001 03-10-1996 09-05-2002 13-06-2000 10-03-1998 02-03-1999 08-12-1998 29-04-2004